CN114736880A - Mutant D497N of glucose oxidase GoxM10 with improved acid stability as well as derivative mutant and application thereof - Google Patents
Mutant D497N of glucose oxidase GoxM10 with improved acid stability as well as derivative mutant and application thereof Download PDFInfo
- Publication number
- CN114736880A CN114736880A CN202210648724.1A CN202210648724A CN114736880A CN 114736880 A CN114736880 A CN 114736880A CN 202210648724 A CN202210648724 A CN 202210648724A CN 114736880 A CN114736880 A CN 114736880A
- Authority
- CN
- China
- Prior art keywords
- ala
- gly
- leu
- val
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03004—Glucose oxidase (1.1.3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/102—Plasmid DNA for yeast
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Plant Pathology (AREA)
- Nutrition Science (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to the technical field of feed biology, and particularly relates to a mutant D497N with improved acid stability and glucose oxidase GoxM10, and a derivative mutant and application thereof. The invention takes glucose oxidase GoxM10 with high thermal stability as a research material, and improves and researches the acid stability of the glucose oxidase GoxM10 by adopting a protein engineering technology. Finally, the mutant with improved acid stability is obtained, thereby promoting the application of Gox in the feed industry.
Description
Technical Field
The invention belongs to the technical field of feed biology, and particularly relates to a mutant D497N with improved acid stability and glucose oxidase GoxM10, and a derivative mutant and application thereof.
Background
Glucose oxidase (Gox; EC 1.1.3.4) is a well-characterized aerobic dehydrogenase that catalyzes the production of d-gluconolactone and hydrogen peroxide from β -d-glucose using an oxygen molecule as an electron acceptor under aerobic conditions, followed by hydrolysis of the d-gluconolactone into gluconic acid and water. In recent years, Gox is generally concerned by the feed industry as a novel antibiotic substitute additive. Gox is used as a substitute of antibiotics and growth promoters and is vital to ensuring the health and production performance of animals on the premise of not damaging the health of human beings. A large number of application studies show that Gox as a green feed additive can be used for preventing gastrointestinal tract infection and diarrhea of livestock and has the effect of promoting animal growth.
It is crucial that Gox is able to maintain high activity in an acidic environment in order to exert its maximum effect in the gastrointestinal tract of animals. Therefore, in order to meet the application of Gox in the feed industry, Gox has good acid stability. The prior art has improved Aspergillus nigerAspergillus niger) Stability of the source Gox, obtainedT 50Mutant GoxM4 increased by 7.5 ℃ and higher than GoxM4T mThe mutant GoxM10 with the temperature being increased by 9 ℃.
Disclosure of Invention
The purpose of the present invention is to provide a mutant of glucose oxidase GoxM10 with improved acid stability.
It is still another object of the present invention to provide a gene encoding the above mutant.
It is still another object of the present invention to provide a recombinant vector comprising the above mutant gene.
It is still another object of the present invention to provide a recombinant strain comprising the above mutant gene.
It is a further object of the present invention to provide the use of the above mutants.
It is a further object of the present invention to provide a method for preparing glucose oxidase with improved stability.
It is a further object of the present invention to provide a method for increasing the glucose oxidase GoxM 10.
According to a specific embodiment of the present invention, site-directed mutagenesis is performed on glucose oxidase having an amino acid sequence shown in SEQ ID NO. 1.
According to the specific embodiment of the invention, the glucose oxidase with the amino acid sequence shown as SEQ ID NO. 1 is subjected to mutation at amino acid positions 113, 193, 362, 497, 535, 113/497, 193/497, 362/497 and 497/535, so as to obtain the glucose oxidase mutant with improved acid stability.
According to the specific embodiment of the invention, H113S mutation is carried out on glucose oxidase GoxM10 with an amino acid sequence shown as SEQ ID NO. 1, so as to obtain a mutant with an amino acid sequence shown as SEQ ID NO. 2 and improved acid stability.
According to the specific embodiment of the invention, the gene for coding the glucose oxidase mutant H113S with improved acid stability is also provided, and the nucleotide sequence of the gene is shown as SEQ ID NO. 3.
According to the specific embodiment of the invention, D193N mutation is carried out on glucose oxidase GoxM10 with the amino acid sequence shown as SEQ ID NO. 1, so as to obtain the mutant with the amino acid sequence shown as SEQ ID NO. 4 and improved acid stability.
According to the specific embodiment of the invention, the gene for coding the glucose oxidase mutant D193N with improved acid stability is also provided, and the nucleotide sequence of the gene is shown as SEQ ID NO. 5.
According to the specific implementation mode of the invention, K362Q mutation is carried out on glucose oxidase GoxM10 with an amino acid sequence shown as SEQ ID NO. 1, so as to obtain the mutant with improved acid stability, with an amino acid sequence shown as SEQ ID NO. 6.
According to the specific embodiment of the invention, the invention also provides a gene for coding the glucose oxidase mutant K362Q with improved acid stability, and the nucleotide sequence of the gene is shown as SEQ ID NO. 7.
According to the specific embodiment of the invention, D497N mutation is carried out on glucose oxidase GoxM10 with the amino acid sequence shown as SEQ ID NO. 1, so as to obtain the mutant with the amino acid sequence shown as SEQ ID NO. 8 and improved acid stability.
According to a specific embodiment of the invention, the gene of the glucose oxidase mutant D497N with improved acid stability is encoded, and the nucleotide sequence is shown as SEQ ID NO. 9.
According to the specific embodiment of the invention, R535N mutation is carried out on glucose oxidase GoxM10 with an amino acid sequence shown as SEQ ID NO. 1, so as to obtain a mutant with an amino acid sequence shown as SEQ ID NO. 10 and improved acid stability.
According to the specific embodiment of the invention, the gene for coding the glucose oxidase mutant R535N with improved acid stability is also provided, and the nucleotide sequence of the gene is shown as SEQ ID NO. 11.
According to the specific embodiment of the invention, H113S/D497N mutation is carried out on glucose oxidase GoxM10 with the amino acid sequence shown as SEQ ID NO. 1, so as to obtain the mutant with the amino acid sequence shown as SEQ ID NO. 12 and improved acid stability.
According to the specific embodiment of the invention, the gene for coding the glucose oxidase mutant H113S/D497N with improved acid stability is also provided, and the nucleotide sequence of the gene is shown as SEQ ID NO. 13.
According to the specific embodiment of the invention, D193N/D497N mutation is carried out on glucose oxidase GoxM10 with the amino acid sequence shown as SEQ ID NO. 1, so as to obtain the mutant with improved acid stability with the amino acid sequence shown as SEQ ID NO. 14.
According to the specific embodiment of the invention, the gene for coding the glucose oxidase mutant D193N/D497N with improved acid stability is also provided, and the nucleotide sequence of the gene is shown as SEQ ID NO. 15.
According to the specific embodiment of the invention, K362Q/D497N mutation is carried out on glucose oxidase GoxM10 with an amino acid sequence shown as SEQ ID NO. 1 to obtain the mutant with improved acid stability with the amino acid sequence shown as SEQ ID NO. 16.
According to the specific embodiment of the invention, the gene for coding the glucose oxidase mutant K362Q/D497N with improved acid stability is also provided, and the nucleotide sequence of the gene is shown as SEQ ID NO. 17.
According to the specific embodiment of the invention, D497N/R535N mutation is carried out on glucose oxidase GoxM10 with the amino acid sequence shown as SEQ ID NO. 1, so as to obtain the mutant with the amino acid sequence shown as SEQ ID NO. 18 and improved acid stability.
According to a specific embodiment of the invention, the gene for coding the glucose oxidase mutant D497N/R535N with improved acid stability is also provided, and the nucleotide sequence of the gene is shown as SEQ ID NO. 19.
According to a specific embodiment of the invention, the invention also provides a gene containing the glucose oxidase mutantThe starting vector of the recombinant expression vector is pPIC9, and the recombinant expression vector is specifically pPIC9-goxm10-H113S,pPIC9-goxm10-D193N,pPIC9-goxm10-K362Q,pPIC9-goxm10-D497N,pPIC9-goxm10-R535N,pPIC9-goxm10-H113S/D497N,pPIC9-goxm10-D193N/D497N,pPIC9-goxm10-K362Q/D497N,pPIC9-goxm10-D497N/R535N。
According to the specific embodiment of the invention, the recombinant strain containing the glucose oxidase mutant gene is also provided, and the starting strain of the recombinant strain is GS115(pPIC 9)-goxm10)。
The method for preparing glucose oxidase with improved stability comprises the following steps:
1) preparing a recombinant vector containing the mutant gene;
2) the recombinant vector transforms a pichia pastoris GS115 expression host;
3) fermenting and culturing the host, and isolating the glucose oxidase.
The invention provides application of the glucose oxidase mutant with improved acid stability, and particularly can be applied to the fields of food and feed.
Compared with GoxM10, the acid stability of the mutant is obviously improved. The optimum pH of mutants D193N, D497N and D193N/D497N was decreased by 1 unit, the optimum reaction pH of double-site mutants H113S/D497N, K362Q/D497N and D497N/R535N was 5.5, and the optimum reaction pH was decreased by 0.5 unit compared with GoxM10, and the optimum pH of the other mutants and GoxM10 were both 6.0. When treated for 30 min under the condition of pH 2.5, relative residual enzyme activities of mutants H113S, D193N, K362Q, D497N, R535N, H113S/D497N, D193N/D497N, K362Q/D497N and D497N/R535N are respectively 22%, 26%, 34%, 24%, 27%, 35%, 25% and 28% which are higher than GoxM10 (21%); after the mutant is treated for 60 min at the conditions of pH 2.75 and 37 ℃, the relative residual enzyme activities of the mutants H113S, D193N, K362Q, D497N, R535N, H113S/D497N, D193N/D497N, K362Q/D497N and D497N/R535N are respectively about 26%, 28%, 26%, 32%, 29%, 47%, 49%, 32% and 43% and are higher than 24% of the relative residual enzyme activity of GoxM 10.
The glucose oxidase mutant provided by the invention can well meet the application requirements in the fields of food, feed and the like, and has a very wide application prospect.
Drawings
FIG. 1 shows acid stability comparison of GoxM10 and the mutant treated at pH 2.5 for 30 min;
FIG. 2 shows a comparison of acid stability of GoxM10 and the mutant treated at pH 2.75 for 60 min;
figure 3 shows the pH optimum comparison of GoxM10 and the mutant.
Detailed Description
Test materials and reagents
1. Bacterial strain and carrier: the expression host isPichia pastoris GS115, expression plasmid vector pPIC 9.
2. Enzymes and other biochemical reagents: endonuclease/high fidelity DNA polymerase and recombinase.
3. Coli LB medium (1% peptone, 0.5% yeast extract, 1% NaCl, pH natural). Pichia pastoris YPD medium (1% yeast extract, 2% peptone, 2% glucose, pH natural); BMGY (1% yeast extract, 2% peptone, 10% amino-free yeast nitrogen source, 0.1% biotin, pH Natural); BMMY (1% yeast extract, 2% peptone, 10% amino-free yeast nitrogen source, 0.1% biotin, 1% methanol, pH natural).
Description of the drawings: the molecular biological experiments, which are not specifically described in the following examples, were performed according to the methods listed in molecular cloning, a laboratory manual (third edition) J. SammBruker, or according to the kit and product instructions.
Example 1 recombinant StrainGS115(pPIC9-goxm10) Preparation of
1. Amplification of nucleic acid sequence of high-thermal stability glucose oxidase GoxM10goxm10
Amplification by PCRgoxm10The gene fragment adopts a double-enzyme cutting method to obtain a vector pPIC9 nucleic acid fragment, and the two are connected by a recombinase to obtain a recombinant plasmid pPIC9-goxm10And transforming Pichia pastoris GS115 to obtain recombinant Pichia pastoris GS115(pPIC9-goxm10). The primers used for PCR were as follows:
GoxM10-F(SEQ ID NO: 20),GoxM10-R(SEQ ID NO: 21)。
wherein, GoxM10-F and GoxM10-R are used for amplifying the gene coding sequence of GoxM 10; the vector pPIC9 was obtained by inoculating the preserved strain to liquid LB medium overnight for culture, and extracting the plasmid.
After the amplification is finished, carrying out nucleic acid electrophoresis detection on the PCR product and the extracted plasmid,goxm10the sizes of the bands of the vector and the pPIC9 are 1746bp and 8088bp respectively, and the vector is usedEcoRI andNotand I, after enzyme digestion, respectively recovering and purifying the PCR product and the enzyme digestion product.
2. Construction of recombinant Strain GS115(pPIC 9)-goxm10)
To be recoveredgoxm10The recombinant plasmid was ligated with the pPIC9 gene fragment by recombinant enzyme, and the recombinant product was transformed into Escherichia coli JM109 competent cells, which were then plated on LB (100. mu.g/mL Amp) for selection. After sequencing is correct, use is made ofBglII restriction Endonuclease the recombinant plasmid pPIC9-goxm10Enzyme digestion is carried out, after enzyme digestion products are recovered, pichia pastoris GS115 competent cells are transformed by electric shock, and a recombinant expression strain GS115(pPIC 9) is obtained-goxm10)。
Example 2 preparation of recombinant mutant Strain GS115
1. Construction of recombinant plasmids with improved stability
Design of mutant primers based on the mutant, using the plasmid pPIC9-goxm10Introducing mutant amino acid by point mutation kit as template, and using PCR product containing mutant amino acidDpnI, digesting to remove a template, transforming the digested PCR product into escherichia coli JM109 competent cells, and carrying out sequencing verification on the escherichia coli JM109 competent cells to obtain escherichia coli pPIC9-goxm10-H113S,pPIC9-goxm10-D193N,pPIC9-goxm10-K362Q,pPIC9-goxm10-D497N,pPIC9-goxm10-R535N, pPIC9-goxm10-H113S/D497N,pPIC9-goxm10-D193N/D497N,pPIC9-goxm10-K362Q/D497N,pPIC9-goxm10D497N/R535N. The primers used are as follows:
Gox-H113S-F(SEQ ID NO:22),Gox-H113S-R(SEQ ID NO:23);Gox-D193N-F(SEQ ID NO:24),Gox-D193N-R(SEQ ID NO:25);Gox-K362Q-F(SEQ ID NO:26),Gox-K362Q-R(SEQ ID NO:27);Gox-D497N-F(SEQ ID NO:28),Gox-D497N-R(SEQ ID NO:29);
Gox-R535N-F(SEQ ID NO:30),Gox-R535N-R(SEQ ID NO:31)。
2. construction of acid-and Heat-Stable recombinant Strain GS115
By usingBglII, carrying out enzyme digestion on the mutation plasmid with correct sequencing, recovering the enzyme digestion product, and then carrying out electric shock transformation on the pichia pastoris GS115 competent cell to obtain a recombinant expression strain GS115(pPIC9-goxm10-H113S),GS115(pPIC9-goxm10-D193N),GS115(pPIC9-goxm10-K362Q),GS115(pPIC9-goxm10-D497N),GS115(pPIC9-goxm10-R535N), GS115(pPIC9-goxm10-H113S/D497N),GS115(pPIC9-goxm10-D193N/D497N),GS115(pPIC9-goxm10-K362Q/D497N),GS115(pPIC9-goxm10-D497N/R535N)。
Example 3 obtaining of glucose oxidase GoxM10 and high acid and Heat stability mutant enzyme proteins
1. Inducible expression of GoxM10 and mutants
Inoculating the obtained recombinant yeast expression strain into 50 mL YPD culture medium with the inoculation amount of 1% for seed liquid culture, culturing at 200 rpm and 30 ℃ for 48 h, then transferring into 400 mL BMGY culture medium with the inoculation amount of 1% for culturing at 200 rpm and 30 ℃ for 48 h, centrifugally collecting thalli, transferring into 200 mL BMMY culture medium, supplementing 1% methanol every 24 h for induction expression, and culturing for 72 h.
2. Purification of GoxM10 and mutants
Centrifuging the bacteria solution after induction expression at 12000 rpm for 10 min, collecting supernatant, concentrating with a 10 kDa membrane package, dialyzing with 10 mM disodium hydrogen phosphate-citric acid buffer solution (pH 6.5), purifying the crude enzyme solution after dialysis with an anion column, wherein the solution A is 10 mM disodium hydrogen phosphate-citric acid buffer solution (pH 6.5), the solution B is solution A, 1M NaCl is added, purifying protein, and collecting eluent.
3. Enzymatic characterization of GoxM10 and mutants
(1) Acid stability assay for GoxM10 and mutants
1 pH stability of GoxM10 and mutants was evaluated using two assays. The method comprises the following steps: the same concentrations of GoxM10 and mutant enzyme solutions were placed in accurately prepared 0.1M disodium hydrogen phosphate-citric acid buffers at pH 2.5, 2.75, 3.0, 4.0, 5.0, 6.0, 7.0 and 8.0, followed by incubation at 37 ℃ for 1 h. And after the heat preservation is finished, measuring the residual enzyme activity under the standard condition, and recording the enzyme activity of the untreated sample as 100%. The second method comprises the following steps: the same concentration of GoxM10 and mutant enzyme solutions was placed in 0.1M disodium hydrogen phosphate-citric acid buffer at pH 2.5, followed by incubation at 37 ℃ for 10 min, 20 min, 30 min, 40 min, 50 min, and 60 min. After the heat preservation is finished, the relative residual enzyme activity of the GoxM10 and the mutant enzyme solution thereof is measured under standard conditions. As shown in fig. 1, when treated at pH 2.5 for 30 min, the relative residual enzyme activities of mutants H113S, D193N, K362Q, D497N, R535N, H113S/D497N, D193N/D497N, K362Q/D497N, and D497N/R535N were 22%, 26%, 34%, 24%, 27%, 35%, 25%, and 28%, respectively, and were increased by about 5%, 24%, 62%, 14%, 29%, 67%, 19%, and 33%, respectively, as compared to GoxM10 (21%). As shown in FIG. 2, the relative residual enzyme activities of the mutants H113S, D193N, K362Q, D497N, R535N, H113S/D497N, D193N/D497N, K362Q/D497N and D497N/R535N are respectively 26%, 28%, 26%, 32%, 29%, 47%, 49%, 32% and 43% after treatment at pH 2.75 and 37 ℃ for 60 min, and are respectively improved by about 8%, 17%, 8%, 33%, 21%, 96%, 104%, 33% and 79% compared with GoxM10 (24%).
(4) pH optimum assay for GoxM10 and mutants
Firstly, substrate mixed liquor for GoxM enzyme activity determination with different pH gradients (3.0, 4.0, 5.0, 6.0, 7.0 and 8.0) is respectively prepared, then, enzyme activity of GoxM10 and a mutant thereof is determined at 30 ℃, the enzyme activity under the condition of the optimal reaction pH is set as 100%, and then, relative enzyme activity under the other pH conditions is calculated, so that the optimal reaction pH of GoxM10 and the mutant thereof can be obtained. As shown in fig. 3, mutants D193N, D497N and D193N/D497N had an optimum pH of 5, which was decreased by one unit compared to GoxM10, mutants H113S/D497N, K362Q/D497N and D497N/R535N had an optimum reaction pH of 5.5, which was decreased by 0.5 unit compared to GoxM10, and mutants H113S, K362Q and R535N had an optimum reaction pH of 6.0 compared to GoxM 10.
The above examples are only for explaining the technical solutions of the present application, and do not limit the scope of protection of the present application.
Sequence listing
<110> Beijing animal husbandry and veterinary institute of Chinese academy of agricultural sciences
<120> mutant D497N with improved acid stability of glucose oxidase GoxM10, and derivative mutant and application thereof
<160> 31
<170> SIPOSequenceListing 1.0
<210> 1
<211> 581
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Gly Ile Glu Ala Ser Leu Leu Thr Asp Pro Lys Glu Val Ala Gly Arg
1 5 10 15
Thr Val Asp Tyr Ile Ile Ala Gly Gly Gly Leu Thr Gly Leu Val Val
20 25 30
Ala Ala Arg Leu Thr Glu Asn Pro Asp Ile Thr Val Leu Val Ile Glu
35 40 45
Ser Gly Ser Tyr Glu Ser Asp Arg Gly Pro Ile Ile Glu Asp Leu Asn
50 55 60
Ala Tyr Gly Lys Ile Phe Gly Ser Ser Val Asp His Ala Tyr Glu Thr
65 70 75 80
Val Cys Leu Ala Thr Asn Asn Arg Thr Ala Leu Ile Arg Ala Gly Asn
85 90 95
Gly Leu Gly Gly Ser Thr Leu Val Asn Gly Gly Thr Trp Thr Arg Pro
100 105 110
His Lys Ala Gln Val Asp Ser Trp Glu Thr Val Phe Gly Asn Glu Gly
115 120 125
Trp Asn Trp Asp Ser Val Ala Ala Tyr Ser Leu Gln Ala Glu Arg Ala
130 135 140
Arg Ala Pro Asn Ala Lys Gln Ile Ala Ala Gly His Tyr Phe Asn Ala
145 150 155 160
Ser Cys His Gly Ile Asn Gly Thr Val His Ala Gly Pro Arg Asp Thr
165 170 175
Gly Asp Asp Tyr Ser Pro Ile Val Lys Ala Leu Met Ser Ala Val Glu
180 185 190
Asp Arg Gly Val Pro Thr Lys Lys Asp Leu Gly Cys Gly Asp Pro His
195 200 205
Gly Val Ser Met Phe Pro Asn Thr Leu His Glu Asp Gln Val Arg Ser
210 215 220
Asp Ala Ala Arg Glu Trp Leu Leu Pro Asn Tyr Gln Arg Pro Asn Leu
225 230 235 240
Gln Val Leu Thr Gly Gln Tyr Val Gly Lys Val Leu Leu Ser Gln Asn
245 250 255
Ala Thr Thr Pro Arg Ala Val Gly Val Glu Phe Gly Thr His Lys Gly
260 265 270
Asn Phe His Asn Val Thr Ala Lys His Glu Val Leu Leu Ala Ala Gly
275 280 285
Ser Ala Val Ser Pro Thr Ile Leu Glu Tyr Ser Gly Ile Gly Met Lys
290 295 300
Ser Ile Leu Glu Pro Leu Gly Ile Lys Thr Val Val Asp Leu Pro Val
305 310 315 320
Gly Leu Asn Leu Gln Asp Gln Thr Thr Ser Thr Val Arg Ser Arg Ile
325 330 335
Thr Ser Ala Gly Ala Gly Gln Gly Gln Ala Ala Trp Phe Ala Thr Phe
340 345 350
Asn Glu Thr Phe Gly Asp Tyr Thr Glu Lys Ala His Glu Leu Leu Asn
355 360 365
Thr Lys Leu Glu Gln Trp Ala Glu Glu Ala Val Ala Arg Gly Gly Phe
370 375 380
His Asn Thr Thr Ala Leu Leu Ile Gln Tyr Glu Asn Tyr Arg Asp Trp
385 390 395 400
Ile Val Lys Asp Asn Val Ala Tyr Ser Glu Leu Phe Leu Asp Thr Ala
405 410 415
Gly Glu Ala Ser Phe Asp Val Trp Asp Leu Leu Pro Phe Thr Arg Gly
420 425 430
Tyr Val His Ile Leu Asp Lys Asp Pro Tyr Leu Arg His Phe Ala Tyr
435 440 445
Asp Pro Gln Tyr Phe Leu Asn Glu Leu Asp Leu Leu Gly Gln Ala Ala
450 455 460
Ala Thr Gln Leu Ala Arg Asn Ile Ser Asn Ser Gly Ala Met Gln Thr
465 470 475 480
Tyr Phe Ala Gly Glu Thr Ile Pro Gly Asp Asn Leu Ala Tyr Asp Ala
485 490 495
Asp Leu Arg Ala Trp Val Glu Tyr Ile Pro Tyr His Phe Arg Pro Asn
500 505 510
Tyr His Gly Val Gly Thr Cys Ser Met Met Pro Lys Glu Met Gly Gly
515 520 525
Val Val Asp Asn Ala Ala Arg Val Tyr Gly Val Gln Gly Leu Arg Val
530 535 540
Ile Asp Gly Ser Ile Pro Pro Thr Gln Met Ser Ser His Val Met Thr
545 550 555 560
Val Phe Tyr Ala Met Ala Leu Lys Ile Ala Asp Ala Val Leu Ala Asp
565 570 575
Tyr Ala Ser Met Gln
580
<210> 2
<211> 581
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Gly Ile Glu Ala Ser Leu Leu Thr Asp Pro Lys Glu Val Ala Gly Arg
1 5 10 15
Thr Val Asp Tyr Ile Ile Ala Gly Gly Gly Leu Thr Gly Leu Val Val
20 25 30
Ala Ala Arg Leu Thr Glu Asn Pro Asp Ile Thr Val Leu Val Ile Glu
35 40 45
Ser Gly Ser Tyr Glu Ser Asp Arg Gly Pro Ile Ile Glu Asp Leu Asn
50 55 60
Ala Tyr Gly Lys Ile Phe Gly Ser Ser Val Asp His Ala Tyr Glu Thr
65 70 75 80
Val Cys Leu Ala Thr Asn Asn Arg Thr Ala Leu Ile Arg Ala Gly Asn
85 90 95
Gly Leu Gly Gly Ser Thr Leu Val Asn Gly Gly Thr Trp Thr Arg Pro
100 105 110
Ser Lys Ala Gln Val Asp Ser Trp Glu Thr Val Phe Gly Asn Glu Gly
115 120 125
Trp Asn Trp Asp Ser Val Ala Ala Tyr Ser Leu Gln Ala Glu Arg Ala
130 135 140
Arg Ala Pro Asn Ala Lys Gln Ile Ala Ala Gly His Tyr Phe Asn Ala
145 150 155 160
Ser Cys His Gly Ile Asn Gly Thr Val His Ala Gly Pro Arg Asp Thr
165 170 175
Gly Asp Asp Tyr Ser Pro Ile Val Lys Ala Leu Met Ser Ala Val Glu
180 185 190
Asp Arg Gly Val Pro Thr Lys Lys Asp Leu Gly Cys Gly Asp Pro His
195 200 205
Gly Val Ser Met Phe Pro Asn Thr Leu His Glu Asp Gln Val Arg Ser
210 215 220
Asp Ala Ala Arg Glu Trp Leu Leu Pro Asn Tyr Gln Arg Pro Asn Leu
225 230 235 240
Ser Val Leu Thr Gly Gln Tyr Val Gly Lys Val Leu Leu Ser Gln Asn
245 250 255
Ala Thr Thr Pro Arg Ala Val Gly Val Glu Phe Gly Thr His Lys Gly
260 265 270
Asn Phe His Asn Val Thr Ala Lys His Glu Val Leu Leu Ala Ala Gly
275 280 285
Ser Ala Val Ser Pro Thr Ile Leu Glu Tyr Ser Gly Ile Gly Met Lys
290 295 300
Ser Ile Leu Glu Pro Leu Gly Ile Lys Thr Val Val Asp Leu Pro Val
305 310 315 320
Gly Leu Asn Leu Gln Asp Gln Thr Thr Ser Thr Val Arg Ser Arg Ile
325 330 335
Thr Ser Ala Gly Ala Gly Gln Gly Gln Ala Ala Trp Phe Ala Thr Phe
340 345 350
Asn Glu Thr Phe Gly Asp Tyr Thr Glu Lys Ala His Glu Leu Leu Asn
355 360 365
Thr Lys Leu Glu Gln Trp Ala Glu Glu Ala Val Ala Arg Gly Gly Phe
370 375 380
His Asn Thr Thr Ala Leu Leu Ile Gln Tyr Glu Asn Tyr Arg Asp Trp
385 390 395 400
Ile Val Lys Asp Asn Val Ala Tyr Ser Glu Leu Phe Leu Asp Thr Ala
405 410 415
Gly Glu Ala Ser Phe Asp Val Trp Asp Leu Leu Pro Phe Thr Arg Gly
420 425 430
Tyr Val His Ile Leu Asp Lys Asp Pro Tyr Leu Arg His Phe Ala Tyr
435 440 445
Asp Pro Gln Tyr Phe Leu Asn Glu Leu Asp Leu Leu Gly Gln Ala Ala
450 455 460
Ala Thr Gln Leu Ala Arg Asn Ile Ser Asn Ser Gly Ala Met Gln Thr
465 470 475 480
Tyr Phe Ala Gly Glu Thr Ile Pro Gly Asp Asn Leu Ala Tyr Asp Ala
485 490 495
Asp Leu Arg Ala Trp Val Glu Tyr Ile Pro Tyr His Phe Arg Pro Asn
500 505 510
Tyr His Gly Val Gly Thr Cys Ser Met Met Pro Lys Glu Met Gly Gly
515 520 525
Val Val Asp Asn Ala Ala Arg Val Tyr Gly Val Gln Gly Leu Arg Val
530 535 540
Ile Asp Gly Ser Ile Pro Pro Thr Gln Met Ser Ser His Val Met Thr
545 550 555 560
Val Phe Tyr Ala Met Ala Leu Lys Ile Ala Asp Ala Val Leu Ala Asp
565 570 575
Tyr Ala Ser Met Gln
580
<210> 3
<211> 1746
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
ggtattgagg cttccttgtt gactgaccca aaggaggtcg ccggtagaac tgttgactac 60
atcattgctg gtggtggatt gactggtttg gttgtcgctg ccagattgac tgagaaccca 120
gacatcaccg ttttggtcat tgagtccggt tcttacgaat ctgatagagg tcctatcatt 180
gaagacttga acgcttacgg taaaatcttc ggatcttccg ttgaccacgc ttacgagact 240
gtctgccttg ccactaacaa tagaaccgct ttgattagag ctggtaacgg tttgggtggt 300
tctactttgg ttaacggagg tacttggacc agaccatcta aggctcaagt tgactcttgg 360
gagaccgtct tcggtaacga aggttggaat tgggattctg tcgcagctta ctccttgcag 420
gccgagagag cccgtgctcc aaacgctaag caaatcgccg caggtcacta cttcaacgcc 480
tcctgtcacg gtattaacgg aactgttcac gctggtccaa gagacaccgg tgacgattac 540
tctcctatcg tcaaggcctt gatgtccgct gttgaagaca gaggtgtccc aactaagaag 600
gacttgggtt gcggagaccc acatggtgtt tctatgttcc ctaacacctt gcacgaggac 660
caagtcagat ccgatgctgc ccgtgaatgg ttgcttccaa actaccaaag acctaacttg 720
caggttttga ccggtcaata cgttggtaag gtccttttgt ctcaaaacgc cactacccca 780
agagctgttg gtgtcgagtt cggaactcac aagggtaact ttcacaatgt taccgctaaa 840
cacgaagtcc ttttggcagc tggttccgct gtttctccaa ctatcttgga gtactctggt 900
atcggaatga agtccatttt ggaaccactt ggtattaaga ccgtcgttga cttgcctgtt 960
ggtctgaact tgcaagacca gactacctct actgtcagat cccgtattac ctccgccggt 1020
gctggacagg gtcaggctgc ctggtttgct actttcaacg agaccttcgg tgactacact 1080
gagaaggctc acgaattgct taacaccaaa ttggaacaat gggctgagga agccgttgct 1140
agaggtggtt tccacaacac taccgctctt ttgatccaat acgagaacta cagagactgg 1200
attgttaagg ataacgtcgc ttactctgaa ttgttcttgg acactgccgg tgaggcttcc 1260
ttcgacgtct gggacttgct gccattcact agaggatacg ttcacatctt ggacaaggac 1320
ccatacttga gacacttcgc ttacgatcct caatacttct tgaacgagtt ggacttgctt 1380
ggtcaggctg ccgctactca attggctaga aacatctcta actccggtgc catgcaaact 1440
tactttgctg gtgaaaccat tccaggtgac aacttggcct acgatgctga cttgagagct 1500
tgggttgaat acattccata ccacttcaga cctaactacc atggtgtcgg aacctgttct 1560
atgatgccaa aggagatggg tggtgtcgtt gacaacgccg ctagagttta cggtgtccag 1620
ggattgagag ttatcgacgg ttctatccca cctactcaaa tgtcctctca cgttatgacc 1680
gtcttctacg ctatggcttt gaagatcgca gacgctgttt tggctgacta cgcctccatg 1740
caataa 1746
<210> 4
<211> 581
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Gly Ile Glu Ala Ser Leu Leu Thr Asp Pro Lys Glu Val Ala Gly Arg
1 5 10 15
Thr Val Asp Tyr Ile Ile Ala Gly Gly Gly Leu Thr Gly Leu Val Val
20 25 30
Ala Ala Arg Leu Thr Glu Asn Pro Asp Ile Thr Val Leu Val Ile Glu
35 40 45
Ser Gly Ser Tyr Glu Ser Asp Arg Gly Pro Ile Ile Glu Asp Leu Asn
50 55 60
Ala Tyr Gly Lys Ile Phe Gly Ser Ser Val Asp His Ala Tyr Glu Thr
65 70 75 80
Val Cys Leu Ala Thr Asn Asn Arg Thr Ala Leu Ile Arg Ala Gly Asn
85 90 95
Gly Leu Gly Gly Ser Thr Leu Val Asn Gly Gly Thr Trp Thr Arg Pro
100 105 110
His Lys Ala Gln Val Asp Ser Trp Glu Thr Val Phe Gly Asn Glu Gly
115 120 125
Trp Asn Trp Asp Ser Val Ala Ala Tyr Ser Leu Gln Ala Glu Arg Ala
130 135 140
Arg Ala Pro Asn Ala Lys Gln Ile Ala Ala Gly His Tyr Phe Asn Ala
145 150 155 160
Ser Cys His Gly Ile Asn Gly Thr Val His Ala Gly Pro Arg Asp Thr
165 170 175
Gly Asp Asp Tyr Ser Pro Ile Val Lys Ala Leu Met Ser Ala Val Glu
180 185 190
Asn Arg Gly Val Pro Thr Lys Lys Asp Leu Gly Cys Gly Asp Pro His
195 200 205
Gly Val Ser Met Phe Pro Asn Thr Leu His Glu Asp Gln Val Arg Ser
210 215 220
Asp Ala Ala Arg Glu Trp Leu Leu Pro Asn Tyr Gln Arg Pro Asn Leu
225 230 235 240
Ser Val Leu Thr Gly Gln Tyr Val Gly Lys Val Leu Leu Ser Gln Asn
245 250 255
Ala Thr Thr Pro Arg Ala Val Gly Val Glu Phe Gly Thr His Lys Gly
260 265 270
Asn Phe His Asn Val Thr Ala Lys His Glu Val Leu Leu Ala Ala Gly
275 280 285
Ser Ala Val Ser Pro Thr Ile Leu Glu Tyr Ser Gly Ile Gly Met Lys
290 295 300
Ser Ile Leu Glu Pro Leu Gly Ile Lys Thr Val Val Asp Leu Pro Val
305 310 315 320
Gly Leu Asn Leu Gln Asp Gln Thr Thr Ser Thr Val Arg Ser Arg Ile
325 330 335
Thr Ser Ala Gly Ala Gly Gln Gly Gln Ala Ala Trp Phe Ala Thr Phe
340 345 350
Asn Glu Thr Phe Gly Asp Tyr Thr Glu Lys Ala His Glu Leu Leu Asn
355 360 365
Thr Lys Leu Glu Gln Trp Ala Glu Glu Ala Val Ala Arg Gly Gly Phe
370 375 380
His Asn Thr Thr Ala Leu Leu Ile Gln Tyr Glu Asn Tyr Arg Asp Trp
385 390 395 400
Ile Val Lys Asp Asn Val Ala Tyr Ser Glu Leu Phe Leu Asp Thr Ala
405 410 415
Gly Glu Ala Ser Phe Asp Val Trp Asp Leu Leu Pro Phe Thr Arg Gly
420 425 430
Tyr Val His Ile Leu Asp Lys Asp Pro Tyr Leu Arg His Phe Ala Tyr
435 440 445
Asp Pro Gln Tyr Phe Leu Asn Glu Leu Asp Leu Leu Gly Gln Ala Ala
450 455 460
Ala Thr Gln Leu Ala Arg Asn Ile Ser Asn Ser Gly Ala Met Gln Thr
465 470 475 480
Tyr Phe Ala Gly Glu Thr Ile Pro Gly Asp Asn Leu Ala Tyr Asp Ala
485 490 495
Asp Leu Arg Ala Trp Val Glu Tyr Ile Pro Tyr His Phe Arg Pro Asn
500 505 510
Tyr His Gly Val Gly Thr Cys Ser Met Met Pro Lys Glu Met Gly Gly
515 520 525
Val Val Asp Asn Ala Ala Arg Val Tyr Gly Val Gln Gly Leu Arg Val
530 535 540
Ile Asp Gly Ser Ile Pro Pro Thr Gln Met Ser Ser His Val Met Thr
545 550 555 560
Val Phe Tyr Ala Met Ala Leu Lys Ile Ala Asp Ala Val Leu Ala Asp
565 570 575
Tyr Ala Ser Met Gln
580
<210> 5
<211> 1746
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ggtattgagg cttccttgtt gactgaccca aaggaggtcg ccggtagaac tgttgactac 60
atcattgctg gtggtggatt gactggtttg gttgtcgctg ccagattgac tgagaaccca 120
gacatcaccg ttttggtcat tgagtccggt tcttacgaat ctgatagagg tcctatcatt 180
gaagacttga acgcttacgg taaaatcttc ggatcttccg ttgaccacgc ttacgagact 240
gtctgccttg ccactaacaa tagaaccgct ttgattagag ctggtaacgg tttgggtggt 300
tctactttgg ttaacggagg tacttggacc agaccacaca aggctcaagt tgactcttgg 360
gagaccgtct tcggtaacga aggttggaat tgggattctg tcgcagctta ctccttgcag 420
gccgagagag cccgtgctcc aaacgctaag caaatcgccg caggtcacta cttcaacgcc 480
tcctgtcacg gtattaacgg aactgttcac gctggtccaa gagacaccgg tgacgattac 540
tctcctatcg tcaaggcctt gatgtccgct gttgaaaaca gaggtgtccc aactaagaag 600
gacttgggtt gcggagaccc acatggtgtt tctatgttcc ctaacacctt gcacgaggac 660
caagtcagat ccgatgctgc ccgtgaatgg ttgcttccaa actaccaaag acctaacttg 720
caggttttga ccggtcaata cgttggtaag gtccttttgt ctcaaaacgc cactacccca 780
agagctgttg gtgtcgagtt cggaactcac aagggtaact ttcacaatgt taccgctaaa 840
cacgaagtcc ttttggcagc tggttccgct gtttctccaa ctatcttgga gtactctggt 900
atcggaatga agtccatttt ggaaccactt ggtattaaga ccgtcgttga cttgcctgtt 960
ggtctgaact tgcaagacca gactacctct actgtcagat cccgtattac ctccgccggt 1020
gctggacagg gtcaggctgc ctggtttgct actttcaacg agaccttcgg tgactacact 1080
gagaaggctc acgaattgct taacaccaaa ttggaacaat gggctgagga agccgttgct 1140
agaggtggtt tccacaacac taccgctctt ttgatccaat acgagaacta cagagactgg 1200
attgttaagg ataacgtcgc ttactctgaa ttgttcttgg acactgccgg tgaggcttcc 1260
ttcgacgtct gggacttgct gccattcact agaggatacg ttcacatctt ggacaaggac 1320
ccatacttga gacacttcgc ttacgatcct caatacttct tgaacgagtt ggacttgctt 1380
ggtcaggctg ccgctactca attggctaga aacatctcta actccggtgc catgcaaact 1440
tactttgctg gtgaaaccat tccaggtgac aacttggcct acgatgctga cttgagagct 1500
tgggttgaat acattccata ccacttcaga cctaactacc atggtgtcgg aacctgttct 1560
atgatgccaa aggagatggg tggtgtcgtt gacaacgccg ctagagttta cggtgtccag 1620
ggattgagag ttatcgacgg ttctatccca cctactcaaa tgtcctctca cgttatgacc 1680
gtcttctacg ctatggcttt gaagatcgca gacgctgttt tggctgacta cgcctccatg 1740
caataa 1746
<210> 6
<211> 581
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 6
Gly Ile Glu Ala Ser Leu Leu Thr Asp Pro Lys Glu Val Ala Gly Arg
1 5 10 15
Thr Val Asp Tyr Ile Ile Ala Gly Gly Gly Leu Thr Gly Leu Val Val
20 25 30
Ala Ala Arg Leu Thr Glu Asn Pro Asp Ile Thr Val Leu Val Ile Glu
35 40 45
Ser Gly Ser Tyr Glu Ser Asp Arg Gly Pro Ile Ile Glu Asp Leu Asn
50 55 60
Ala Tyr Gly Lys Ile Phe Gly Ser Ser Val Asp His Ala Tyr Glu Thr
65 70 75 80
Val Cys Leu Ala Thr Asn Asn Arg Thr Ala Leu Ile Arg Ala Gly Asn
85 90 95
Gly Leu Gly Gly Ser Thr Leu Val Asn Gly Gly Thr Trp Thr Arg Pro
100 105 110
His Lys Ala Gln Val Asp Ser Trp Glu Thr Val Phe Gly Asn Glu Gly
115 120 125
Trp Asn Trp Asp Ser Val Ala Ala Tyr Ser Leu Gln Ala Glu Arg Ala
130 135 140
Arg Ala Pro Asn Ala Lys Gln Ile Ala Ala Gly His Tyr Phe Asn Ala
145 150 155 160
Ser Cys His Gly Ile Asn Gly Thr Val His Ala Gly Pro Arg Asp Thr
165 170 175
Gly Asp Asp Tyr Ser Pro Ile Val Lys Ala Leu Met Ser Ala Val Glu
180 185 190
Asp Arg Gly Val Pro Thr Lys Lys Asp Leu Gly Cys Gly Asp Pro His
195 200 205
Gly Val Ser Met Phe Pro Asn Thr Leu His Glu Asp Gln Val Arg Ser
210 215 220
Asp Ala Ala Arg Glu Trp Leu Leu Pro Asn Tyr Gln Arg Pro Asn Leu
225 230 235 240
Ser Val Leu Thr Gly Gln Tyr Val Gly Lys Val Leu Leu Ser Gln Asn
245 250 255
Ala Thr Thr Pro Arg Ala Val Gly Val Glu Phe Gly Thr His Lys Gly
260 265 270
Asn Phe His Asn Val Thr Ala Lys His Glu Val Leu Leu Ala Ala Gly
275 280 285
Ser Ala Val Ser Pro Thr Ile Leu Glu Tyr Ser Gly Ile Gly Met Lys
290 295 300
Ser Ile Leu Glu Pro Leu Gly Ile Lys Thr Val Val Asp Leu Pro Val
305 310 315 320
Gly Leu Asn Leu Gln Asp Gln Thr Thr Ser Thr Val Arg Ser Arg Ile
325 330 335
Thr Ser Ala Gly Ala Gly Gln Gly Gln Ala Ala Trp Phe Ala Thr Phe
340 345 350
Asn Glu Thr Phe Gly Asp Tyr Thr Glu Gln Ala His Glu Leu Leu Asn
355 360 365
Thr Lys Leu Glu Gln Trp Ala Glu Glu Ala Val Ala Arg Gly Gly Phe
370 375 380
His Asn Thr Thr Ala Leu Leu Ile Gln Tyr Glu Asn Tyr Arg Asp Trp
385 390 395 400
Ile Val Lys Asp Asn Val Ala Tyr Ser Glu Leu Phe Leu Asp Thr Ala
405 410 415
Gly Glu Ala Ser Phe Asp Val Trp Asp Leu Leu Pro Phe Thr Arg Gly
420 425 430
Tyr Val His Ile Leu Asp Lys Asp Pro Tyr Leu Arg His Phe Ala Tyr
435 440 445
Asp Pro Gln Tyr Phe Leu Asn Glu Leu Asp Leu Leu Gly Gln Ala Ala
450 455 460
Ala Thr Gln Leu Ala Arg Asn Ile Ser Asn Ser Gly Ala Met Gln Thr
465 470 475 480
Tyr Phe Ala Gly Glu Thr Ile Pro Gly Asp Asn Leu Ala Tyr Asp Ala
485 490 495
Asp Leu Arg Ala Trp Val Glu Tyr Ile Pro Tyr His Phe Arg Pro Asn
500 505 510
Tyr His Gly Val Gly Thr Cys Ser Met Met Pro Lys Glu Met Gly Gly
515 520 525
Val Val Asp Asn Ala Ala Arg Val Tyr Gly Val Gln Gly Leu Arg Val
530 535 540
Ile Asp Gly Ser Ile Pro Pro Thr Gln Met Ser Ser His Val Met Thr
545 550 555 560
Val Phe Tyr Ala Met Ala Leu Lys Ile Ala Asp Ala Val Leu Ala Asp
565 570 575
Tyr Ala Ser Met Gln
580
<210> 7
<211> 1746
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
ggtattgagg cttccttgtt gactgaccca aaggaggtcg ccggtagaac tgttgactac 60
atcattgctg gtggtggatt gactggtttg gttgtcgctg ccagattgac tgagaaccca 120
gacatcaccg ttttggtcat tgagtccggt tcttacgaat ctgatagagg tcctatcatt 180
gaagacttga acgcttacgg taaaatcttc ggatcttccg ttgaccacgc ttacgagact 240
gtctgccttg ccactaacaa tagaaccgct ttgattagag ctggtaacgg tttgggtggt 300
tctactttgg ttaacggagg tacttggacc agaccacaca aggctcaagt tgactcttgg 360
gagaccgtct tcggtaacga aggttggaat tgggattctg tcgcagctta ctccttgcag 420
gccgagagag cccgtgctcc aaacgctaag caaatcgccg caggtcacta cttcaacgcc 480
tcctgtcacg gtattaacgg aactgttcac gctggtccaa gagacaccgg tgacgattac 540
tctcctatcg tcaaggcctt gatgtccgct gttgaagaca gaggtgtccc aactaagaag 600
gacttgggtt gcggagaccc acatggtgtt tctatgttcc ctaacacctt gcacgaggac 660
caagtcagat ccgatgctgc ccgtgaatgg ttgcttccaa actaccaaag acctaacttg 720
caggttttga ccggtcaata cgttggtaag gtccttttgt ctcaaaacgc cactacccca 780
agagctgttg gtgtcgagtt cggaactcac aagggtaact ttcacaatgt taccgctaaa 840
cacgaagtcc ttttggcagc tggttccgct gtttctccaa ctatcttgga gtactctggt 900
atcggaatga agtccatttt ggaaccactt ggtattaaga ccgtcgttga cttgcctgtt 960
ggtctgaact tgcaagacca gactacctct actgtcagat cccgtattac ctccgccggt 1020
gctggacagg gtcaggctgc ctggtttgct actttcaacg agaccttcgg tgactacact 1080
gagcaagctc acgaattgct taacaccaaa ttggaacaat gggctgagga agccgttgct 1140
agaggtggtt tccacaacac taccgctctt ttgatccaat acgagaacta cagagactgg 1200
attgttaagg ataacgtcgc ttactctgaa ttgttcttgg acactgccgg tgaggcttcc 1260
ttcgacgtct gggacttgct gccattcact agaggatacg ttcacatctt ggacaaggac 1320
ccatacttga gacacttcgc ttacgatcct caatacttct tgaacgagtt ggacttgctt 1380
ggtcaggctg ccgctactca attggctaga aacatctcta actccggtgc catgcaaact 1440
tactttgctg gtgaaaccat tccaggtgac aacttggcct acgatgctga cttgagagct 1500
tgggttgaat acattccata ccacttcaga cctaactacc atggtgtcgg aacctgttct 1560
atgatgccaa aggagatggg tggtgtcgtt gacaacgccg ctagagttta cggtgtccag 1620
ggattgagag ttatcgacgg ttctatccca cctactcaaa tgtcctctca cgttatgacc 1680
gtcttctacg ctatggcttt gaagatcgca gacgctgttt tggctgacta cgcctccatg 1740
caataa 1746
<210> 8
<211> 581
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 8
Gly Ile Glu Ala Ser Leu Leu Thr Asp Pro Lys Glu Val Ala Gly Arg
1 5 10 15
Thr Val Asp Tyr Ile Ile Ala Gly Gly Gly Leu Thr Gly Leu Val Val
20 25 30
Ala Ala Arg Leu Thr Glu Asn Pro Asp Ile Thr Val Leu Val Ile Glu
35 40 45
Ser Gly Ser Tyr Glu Ser Asp Arg Gly Pro Ile Ile Glu Asp Leu Asn
50 55 60
Ala Tyr Gly Lys Ile Phe Gly Ser Ser Val Asp His Ala Tyr Glu Thr
65 70 75 80
Val Cys Leu Ala Thr Asn Asn Arg Thr Ala Leu Ile Arg Ala Gly Asn
85 90 95
Gly Leu Gly Gly Ser Thr Leu Val Asn Gly Gly Thr Trp Thr Arg Pro
100 105 110
His Lys Ala Gln Val Asp Ser Trp Glu Thr Val Phe Gly Asn Glu Gly
115 120 125
Trp Asn Trp Asp Ser Val Ala Ala Tyr Ser Leu Gln Ala Glu Arg Ala
130 135 140
Arg Ala Pro Asn Ala Lys Gln Ile Ala Ala Gly His Tyr Phe Asn Ala
145 150 155 160
Ser Cys His Gly Ile Asn Gly Thr Val His Ala Gly Pro Arg Asp Thr
165 170 175
Gly Asp Asp Tyr Ser Pro Ile Val Lys Ala Leu Met Ser Ala Val Glu
180 185 190
Asp Arg Gly Val Pro Thr Lys Lys Asp Leu Gly Cys Gly Asp Pro His
195 200 205
Gly Val Ser Met Phe Pro Asn Thr Leu His Glu Asp Gln Val Arg Ser
210 215 220
Asp Ala Ala Arg Glu Trp Leu Leu Pro Asn Tyr Gln Arg Pro Asn Leu
225 230 235 240
Ser Val Leu Thr Gly Gln Tyr Val Gly Lys Val Leu Leu Ser Gln Asn
245 250 255
Ala Thr Thr Pro Arg Ala Val Gly Val Glu Phe Gly Thr His Lys Gly
260 265 270
Asn Phe His Asn Val Thr Ala Lys His Glu Val Leu Leu Ala Ala Gly
275 280 285
Ser Ala Val Ser Pro Thr Ile Leu Glu Tyr Ser Gly Ile Gly Met Lys
290 295 300
Ser Ile Leu Glu Pro Leu Gly Ile Lys Thr Val Val Asp Leu Pro Val
305 310 315 320
Gly Leu Asn Leu Gln Asp Gln Thr Thr Ser Thr Val Arg Ser Arg Ile
325 330 335
Thr Ser Ala Gly Ala Gly Gln Gly Gln Ala Ala Trp Phe Ala Thr Phe
340 345 350
Asn Glu Thr Phe Gly Asp Tyr Thr Glu Lys Ala His Glu Leu Leu Asn
355 360 365
Thr Lys Leu Glu Gln Trp Ala Glu Glu Ala Val Ala Arg Gly Gly Phe
370 375 380
His Asn Thr Thr Ala Leu Leu Ile Gln Tyr Glu Asn Tyr Arg Asp Trp
385 390 395 400
Ile Val Lys Asp Asn Val Ala Tyr Ser Glu Leu Phe Leu Asp Thr Ala
405 410 415
Gly Glu Ala Ser Phe Asp Val Trp Asp Leu Leu Pro Phe Thr Arg Gly
420 425 430
Tyr Val His Ile Leu Asp Lys Asp Pro Tyr Leu Arg His Phe Ala Tyr
435 440 445
Asp Pro Gln Tyr Phe Leu Asn Glu Leu Asp Leu Leu Gly Gln Ala Ala
450 455 460
Ala Thr Gln Leu Ala Arg Asn Ile Ser Asn Ser Gly Ala Met Gln Thr
465 470 475 480
Tyr Phe Ala Gly Glu Thr Ile Pro Gly Asp Asn Leu Ala Tyr Asp Ala
485 490 495
Asn Leu Arg Ala Trp Val Glu Tyr Ile Pro Tyr His Phe Arg Pro Asn
500 505 510
Tyr His Gly Val Gly Thr Cys Ser Met Met Pro Lys Glu Met Gly Gly
515 520 525
Val Val Asp Asn Ala Ala Arg Val Tyr Gly Val Gln Gly Leu Arg Val
530 535 540
Ile Asp Gly Ser Ile Pro Pro Thr Gln Met Ser Ser His Val Met Thr
545 550 555 560
Val Phe Tyr Ala Met Ala Leu Lys Ile Ala Asp Ala Val Leu Ala Asp
565 570 575
Tyr Ala Ser Met Gln
580
<210> 9
<211> 1746
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
ggtattgagg cttccttgtt gactgaccca aaggaggtcg ccggtagaac tgttgactac 60
atcattgctg gtggtggatt gactggtttg gttgtcgctg ccagattgac tgagaaccca 120
gacatcaccg ttttggtcat tgagtccggt tcttacgaat ctgatagagg tcctatcatt 180
gaagacttga acgcttacgg taaaatcttc ggatcttccg ttgaccacgc ttacgagact 240
gtctgccttg ccactaacaa tagaaccgct ttgattagag ctggtaacgg tttgggtggt 300
tctactttgg ttaacggagg tacttggacc agaccacaca aggctcaagt tgactcttgg 360
gagaccgtct tcggtaacga aggttggaat tgggattctg tcgcagctta ctccttgcag 420
gccgagagag cccgtgctcc aaacgctaag caaatcgccg caggtcacta cttcaacgcc 480
tcctgtcacg gtattaacgg aactgttcac gctggtccaa gagacaccgg tgacgattac 540
tctcctatcg tcaaggcctt gatgtccgct gttgaagaca gaggtgtccc aactaagaag 600
gacttgggtt gcggagaccc acatggtgtt tctatgttcc ctaacacctt gcacgaggac 660
caagtcagat ccgatgctgc ccgtgaatgg ttgcttccaa actaccaaag acctaacttg 720
caggttttga ccggtcaata cgttggtaag gtccttttgt ctcaaaacgc cactacccca 780
agagctgttg gtgtcgagtt cggaactcac aagggtaact ttcacaatgt taccgctaaa 840
cacgaagtcc ttttggcagc tggttccgct gtttctccaa ctatcttgga gtactctggt 900
atcggaatga agtccatttt ggaaccactt ggtattaaga ccgtcgttga cttgcctgtt 960
ggtctgaact tgcaagacca gactacctct actgtcagat cccgtattac ctccgccggt 1020
gctggacagg gtcaggctgc ctggtttgct actttcaacg agaccttcgg tgactacact 1080
gagaaggctc acgaattgct taacaccaaa ttggaacaat gggctgagga agccgttgct 1140
agaggtggtt tccacaacac taccgctctt ttgatccaat acgagaacta cagagactgg 1200
attgttaagg ataacgtcgc ttactctgaa ttgttcttgg acactgccgg tgaggcttcc 1260
ttcgacgtct gggacttgct gccattcact agaggatacg ttcacatctt ggacaaggac 1320
ccatacttga gacacttcgc ttacgatcct caatacttct tgaacgagtt ggacttgctt 1380
ggtcaggctg ccgctactca attggctaga aacatctcta actccggtgc catgcaaact 1440
tactttgctg gtgaaaccat tccaggtgac aacttggcct acgatgctaa cttgagagct 1500
tgggttgaat acattccata ccacttcaga cctaactacc atggtgtcgg aacctgttct 1560
atgatgccaa aggagatggg tggtgtcgtt gacaacgccg ctagagttta cggtgtccag 1620
ggattgagag ttatcgacgg ttctatccca cctactcaaa tgtcctctca cgttatgacc 1680
gtcttctacg ctatggcttt gaagatcgca gacgctgttt tggctgacta cgcctccatg 1740
caataa 1746
<210> 10
<211> 581
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 10
Gly Ile Glu Ala Ser Leu Leu Thr Asp Pro Lys Glu Val Ala Gly Arg
1 5 10 15
Thr Val Asp Tyr Ile Ile Ala Gly Gly Gly Leu Thr Gly Leu Val Val
20 25 30
Ala Ala Arg Leu Thr Glu Asn Pro Asp Ile Thr Val Leu Val Ile Glu
35 40 45
Ser Gly Ser Tyr Glu Ser Asp Arg Gly Pro Ile Ile Glu Asp Leu Asn
50 55 60
Ala Tyr Gly Lys Ile Phe Gly Ser Ser Val Asp His Ala Tyr Glu Thr
65 70 75 80
Val Cys Leu Ala Thr Asn Asn Arg Thr Ala Leu Ile Arg Ala Gly Asn
85 90 95
Gly Leu Gly Gly Ser Thr Leu Val Asn Gly Gly Thr Trp Thr Arg Pro
100 105 110
His Lys Ala Gln Val Asp Ser Trp Glu Thr Val Phe Gly Asn Glu Gly
115 120 125
Trp Asn Trp Asp Ser Val Ala Ala Tyr Ser Leu Gln Ala Glu Arg Ala
130 135 140
Arg Ala Pro Asn Ala Lys Gln Ile Ala Ala Gly His Tyr Phe Asn Ala
145 150 155 160
Ser Cys His Gly Ile Asn Gly Thr Val His Ala Gly Pro Arg Asp Thr
165 170 175
Gly Asp Asp Tyr Ser Pro Ile Val Lys Ala Leu Met Ser Ala Val Glu
180 185 190
Asp Arg Gly Val Pro Thr Lys Lys Asp Leu Gly Cys Gly Asp Pro His
195 200 205
Gly Val Ser Met Phe Pro Asn Thr Leu His Glu Asp Gln Val Arg Ser
210 215 220
Asp Ala Ala Arg Glu Trp Leu Leu Pro Asn Tyr Gln Arg Pro Asn Leu
225 230 235 240
Ser Val Leu Thr Gly Gln Tyr Val Gly Lys Val Leu Leu Ser Gln Asn
245 250 255
Ala Thr Thr Pro Arg Ala Val Gly Val Glu Phe Gly Thr His Lys Gly
260 265 270
Asn Phe His Asn Val Thr Ala Lys His Glu Val Leu Leu Ala Ala Gly
275 280 285
Ser Ala Val Ser Pro Thr Ile Leu Glu Tyr Ser Gly Ile Gly Met Lys
290 295 300
Ser Ile Leu Glu Pro Leu Gly Ile Lys Thr Val Val Asp Leu Pro Val
305 310 315 320
Gly Leu Asn Leu Gln Asp Gln Thr Thr Ser Thr Val Arg Ser Arg Ile
325 330 335
Thr Ser Ala Gly Ala Gly Gln Gly Gln Ala Ala Trp Phe Ala Thr Phe
340 345 350
Asn Glu Thr Phe Gly Asp Tyr Thr Glu Lys Ala His Glu Leu Leu Asn
355 360 365
Thr Lys Leu Glu Gln Trp Ala Glu Glu Ala Val Ala Arg Gly Gly Phe
370 375 380
His Asn Thr Thr Ala Leu Leu Ile Gln Tyr Glu Asn Tyr Arg Asp Trp
385 390 395 400
Ile Val Lys Asp Asn Val Ala Tyr Ser Glu Leu Phe Leu Asp Thr Ala
405 410 415
Gly Glu Ala Ser Phe Asp Val Trp Asp Leu Leu Pro Phe Thr Arg Gly
420 425 430
Tyr Val His Ile Leu Asp Lys Asp Pro Tyr Leu Arg His Phe Ala Tyr
435 440 445
Asp Pro Gln Tyr Phe Leu Asn Glu Leu Asp Leu Leu Gly Gln Ala Ala
450 455 460
Ala Thr Gln Leu Ala Arg Asn Ile Ser Asn Ser Gly Ala Met Gln Thr
465 470 475 480
Tyr Phe Ala Gly Glu Thr Ile Pro Gly Asp Asn Leu Ala Tyr Asp Ala
485 490 495
Asp Leu Arg Ala Trp Val Glu Tyr Ile Pro Tyr His Phe Arg Pro Asn
500 505 510
Tyr His Gly Val Gly Thr Cys Ser Met Met Pro Lys Glu Met Gly Gly
515 520 525
Val Val Asp Asn Ala Ala Asn Val Tyr Gly Val Gln Gly Leu Arg Val
530 535 540
Ile Asp Gly Ser Ile Pro Pro Thr Gln Met Ser Ser His Val Met Thr
545 550 555 560
Val Phe Tyr Ala Met Ala Leu Lys Ile Ala Asp Ala Val Leu Ala Asp
565 570 575
Tyr Ala Ser Met Gln
580
<210> 11
<211> 1746
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
ggtattgagg cttccttgtt gactgaccca aaggaggtcg ccggtagaac tgttgactac 60
atcattgctg gtggtggatt gactggtttg gttgtcgctg ccagattgac tgagaaccca 120
gacatcaccg ttttggtcat tgagtccggt tcttacgaat ctgatagagg tcctatcatt 180
gaagacttga acgcttacgg taaaatcttc ggatcttccg ttgaccacgc ttacgagact 240
gtctgccttg ccactaacaa tagaaccgct ttgattagag ctggtaacgg tttgggtggt 300
tctactttgg ttaacggagg tacttggacc agaccacaca aggctcaagt tgactcttgg 360
gagaccgtct tcggtaacga aggttggaat tgggattctg tcgcagctta ctccttgcag 420
gccgagagag cccgtgctcc aaacgctaag caaatcgccg caggtcacta cttcaacgcc 480
tcctgtcacg gtattaacgg aactgttcac gctggtccaa gagacaccgg tgacgattac 540
tctcctatcg tcaaggcctt gatgtccgct gttgaagaca gaggtgtccc aactaagaag 600
gacttgggtt gcggagaccc acatggtgtt tctatgttcc ctaacacctt gcacgaggac 660
caagtcagat ccgatgctgc ccgtgaatgg ttgcttccaa actaccaaag acctaacttg 720
caggttttga ccggtcaata cgttggtaag gtccttttgt ctcaaaacgc cactacccca 780
agagctgttg gtgtcgagtt cggaactcac aagggtaact ttcacaatgt taccgctaaa 840
cacgaagtcc ttttggcagc tggttccgct gtttctccaa ctatcttgga gtactctggt 900
atcggaatga agtccatttt ggaaccactt ggtattaaga ccgtcgttga cttgcctgtt 960
ggtctgaact tgcaagacca gactacctct actgtcagat cccgtattac ctccgccggt 1020
gctggacagg gtcaggctgc ctggtttgct actttcaacg agaccttcgg tgactacact 1080
gagaaggctc acgaattgct taacaccaaa ttggaacaat gggctgagga agccgttgct 1140
agaggtggtt tccacaacac taccgctctt ttgatccaat acgagaacta cagagactgg 1200
attgttaagg ataacgtcgc ttactctgaa ttgttcttgg acactgccgg tgaggcttcc 1260
ttcgacgtct gggacttgct gccattcact agaggatacg ttcacatctt ggacaaggac 1320
ccatacttga gacacttcgc ttacgatcct caatacttct tgaacgagtt ggacttgctt 1380
ggtcaggctg ccgctactca attggctaga aacatctcta actccggtgc catgcaaact 1440
tactttgctg gtgaaaccat tccaggtgac aacttggcct acgatgctga cttgagagct 1500
tgggttgaat acattccata ccacttcaga cctaactacc atggtgtcgg aacctgttct 1560
atgatgccaa aggagatggg tggtgtcgtt gacaacgccg ctaacgttta cggtgtccag 1620
ggattgagag ttatcgacgg ttctatccca cctactcaaa tgtcctctca cgttatgacc 1680
gtcttctacg ctatggcttt gaagatcgca gacgctgttt tggctgacta cgcctccatg 1740
caataa 1746
<210> 12
<211> 581
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 12
Gly Ile Glu Ala Ser Leu Leu Thr Asp Pro Lys Glu Val Ala Gly Arg
1 5 10 15
Thr Val Asp Tyr Ile Ile Ala Gly Gly Gly Leu Thr Gly Leu Val Val
20 25 30
Ala Ala Arg Leu Thr Glu Asn Pro Asp Ile Thr Val Leu Val Ile Glu
35 40 45
Ser Gly Ser Tyr Glu Ser Asp Arg Gly Pro Ile Ile Glu Asp Leu Asn
50 55 60
Ala Tyr Gly Lys Ile Phe Gly Ser Ser Val Asp His Ala Tyr Glu Thr
65 70 75 80
Val Cys Leu Ala Thr Asn Asn Arg Thr Ala Leu Ile Arg Ala Gly Asn
85 90 95
Gly Leu Gly Gly Ser Thr Leu Val Asn Gly Gly Thr Trp Thr Arg Pro
100 105 110
Ser Lys Ala Gln Val Asp Ser Trp Glu Thr Val Phe Gly Asn Glu Gly
115 120 125
Trp Asn Trp Asp Ser Val Ala Ala Tyr Ser Leu Gln Ala Glu Arg Ala
130 135 140
Arg Ala Pro Asn Ala Lys Gln Ile Ala Ala Gly His Tyr Phe Asn Ala
145 150 155 160
Ser Cys His Gly Ile Asn Gly Thr Val His Ala Gly Pro Arg Asp Thr
165 170 175
Gly Asp Asp Tyr Ser Pro Ile Val Lys Ala Leu Met Ser Ala Val Glu
180 185 190
Asp Arg Gly Val Pro Thr Lys Lys Asp Leu Gly Cys Gly Asp Pro His
195 200 205
Gly Val Ser Met Phe Pro Asn Thr Leu His Glu Asp Gln Val Arg Ser
210 215 220
Asp Ala Ala Arg Glu Trp Leu Leu Pro Asn Tyr Gln Arg Pro Asn Leu
225 230 235 240
Ser Val Leu Thr Gly Gln Tyr Val Gly Lys Val Leu Leu Ser Gln Asn
245 250 255
Ala Thr Thr Pro Arg Ala Val Gly Val Glu Phe Gly Thr His Lys Gly
260 265 270
Asn Phe His Asn Val Thr Ala Lys His Glu Val Leu Leu Ala Ala Gly
275 280 285
Ser Ala Val Ser Pro Thr Ile Leu Glu Tyr Ser Gly Ile Gly Met Lys
290 295 300
Ser Ile Leu Glu Pro Leu Gly Ile Lys Thr Val Val Asp Leu Pro Val
305 310 315 320
Gly Leu Asn Leu Gln Asp Gln Thr Thr Ser Thr Val Arg Ser Arg Ile
325 330 335
Thr Ser Ala Gly Ala Gly Gln Gly Gln Ala Ala Trp Phe Ala Thr Phe
340 345 350
Asn Glu Thr Phe Gly Asp Tyr Thr Glu Lys Ala His Glu Leu Leu Asn
355 360 365
Thr Lys Leu Glu Gln Trp Ala Glu Glu Ala Val Ala Arg Gly Gly Phe
370 375 380
His Asn Thr Thr Ala Leu Leu Ile Gln Tyr Glu Asn Tyr Arg Asp Trp
385 390 395 400
Ile Val Lys Asp Asn Val Ala Tyr Ser Glu Leu Phe Leu Asp Thr Ala
405 410 415
Gly Glu Ala Ser Phe Asp Val Trp Asp Leu Leu Pro Phe Thr Arg Gly
420 425 430
Tyr Val His Ile Leu Asp Lys Asp Pro Tyr Leu Arg His Phe Ala Tyr
435 440 445
Asp Pro Gln Tyr Phe Leu Asn Glu Leu Asp Leu Leu Gly Gln Ala Ala
450 455 460
Ala Thr Gln Leu Ala Arg Asn Ile Ser Asn Ser Gly Ala Met Gln Thr
465 470 475 480
Tyr Phe Ala Gly Glu Thr Ile Pro Gly Asp Asn Leu Ala Tyr Asp Ala
485 490 495
Asn Leu Arg Ala Trp Val Glu Tyr Ile Pro Tyr His Phe Arg Pro Asn
500 505 510
Tyr His Gly Val Gly Thr Cys Ser Met Met Pro Lys Glu Met Gly Gly
515 520 525
Val Val Asp Asn Ala Ala Arg Val Tyr Gly Val Gln Gly Leu Arg Val
530 535 540
Ile Asp Gly Ser Ile Pro Pro Thr Gln Met Ser Ser His Val Met Thr
545 550 555 560
Val Phe Tyr Ala Met Ala Leu Lys Ile Ala Asp Ala Val Leu Ala Asp
565 570 575
Tyr Ala Ser Met Gln
580
<210> 13
<211> 1746
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
ggtattgagg cttccttgtt gactgaccca aaggaggtcg ccggtagaac tgttgactac 60
atcattgctg gtggtggatt gactggtttg gttgtcgctg ccagattgac tgagaaccca 120
gacatcaccg ttttggtcat tgagtccggt tcttacgaat ctgatagagg tcctatcatt 180
gaagacttga acgcttacgg taaaatcttc ggatcttccg ttgaccacgc ttacgagact 240
gtctgccttg ccactaacaa tagaaccgct ttgattagag ctggtaacgg tttgggtggt 300
tctactttgg ttaacggagg tacttggacc agaccatcta aggctcaagt tgactcttgg 360
gagaccgtct tcggtaacga aggttggaat tgggattctg tcgcagctta ctccttgcag 420
gccgagagag cccgtgctcc aaacgctaag caaatcgccg caggtcacta cttcaacgcc 480
tcctgtcacg gtattaacgg aactgttcac gctggtccaa gagacaccgg tgacgattac 540
tctcctatcg tcaaggcctt gatgtccgct gttgaagaca gaggtgtccc aactaagaag 600
gacttgggtt gcggagaccc acatggtgtt tctatgttcc ctaacacctt gcacgaggac 660
caagtcagat ccgatgctgc ccgtgaatgg ttgcttccaa actaccaaag acctaacttg 720
caggttttga ccggtcaata cgttggtaag gtccttttgt ctcaaaacgc cactacccca 780
agagctgttg gtgtcgagtt cggaactcac aagggtaact ttcacaatgt taccgctaaa 840
cacgaagtcc ttttggcagc tggttccgct gtttctccaa ctatcttgga gtactctggt 900
atcggaatga agtccatttt ggaaccactt ggtattaaga ccgtcgttga cttgcctgtt 960
ggtctgaact tgcaagacca gactacctct actgtcagat cccgtattac ctccgccggt 1020
gctggacagg gtcaggctgc ctggtttgct actttcaacg agaccttcgg tgactacact 1080
gagaaggctc acgaattgct taacaccaaa ttggaacaat gggctgagga agccgttgct 1140
agaggtggtt tccacaacac taccgctctt ttgatccaat acgagaacta cagagactgg 1200
attgttaagg ataacgtcgc ttactctgaa ttgttcttgg acactgccgg tgaggcttcc 1260
ttcgacgtct gggacttgct gccattcact agaggatacg ttcacatctt ggacaaggac 1320
ccatacttga gacacttcgc ttacgatcct caatacttct tgaacgagtt ggacttgctt 1380
ggtcaggctg ccgctactca attggctaga aacatctcta actccggtgc catgcaaact 1440
tactttgctg gtgaaaccat tccaggtgac aacttggcct acgatgctaa cttgagagct 1500
tgggttgaat acattccata ccacttcaga cctaactacc atggtgtcgg aacctgttct 1560
atgatgccaa aggagatggg tggtgtcgtt gacaacgccg ctagagttta cggtgtccag 1620
ggattgagag ttatcgacgg ttctatccca cctactcaaa tgtcctctca cgttatgacc 1680
gtcttctacg ctatggcttt gaagatcgca gacgctgttt tggctgacta cgcctccatg 1740
caataa 1746
<210> 14
<211> 581
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 14
Gly Ile Glu Ala Ser Leu Leu Thr Asp Pro Lys Glu Val Ala Gly Arg
1 5 10 15
Thr Val Asp Tyr Ile Ile Ala Gly Gly Gly Leu Thr Gly Leu Val Val
20 25 30
Ala Ala Arg Leu Thr Glu Asn Pro Asp Ile Thr Val Leu Val Ile Glu
35 40 45
Ser Gly Ser Tyr Glu Ser Asp Arg Gly Pro Ile Ile Glu Asp Leu Asn
50 55 60
Ala Tyr Gly Lys Ile Phe Gly Ser Ser Val Asp His Ala Tyr Glu Thr
65 70 75 80
Val Cys Leu Ala Thr Asn Asn Arg Thr Ala Leu Ile Arg Ala Gly Asn
85 90 95
Gly Leu Gly Gly Ser Thr Leu Val Asn Gly Gly Thr Trp Thr Arg Pro
100 105 110
His Lys Ala Gln Val Asp Ser Trp Glu Thr Val Phe Gly Asn Glu Gly
115 120 125
Trp Asn Trp Asp Ser Val Ala Ala Tyr Ser Leu Gln Ala Glu Arg Ala
130 135 140
Arg Ala Pro Asn Ala Lys Gln Ile Ala Ala Gly His Tyr Phe Asn Ala
145 150 155 160
Ser Cys His Gly Ile Asn Gly Thr Val His Ala Gly Pro Arg Asp Thr
165 170 175
Gly Asp Asp Tyr Ser Pro Ile Val Lys Ala Leu Met Ser Ala Val Glu
180 185 190
Asn Arg Gly Val Pro Thr Lys Lys Asp Leu Gly Cys Gly Asp Pro His
195 200 205
Gly Val Ser Met Phe Pro Asn Thr Leu His Glu Asp Gln Val Arg Ser
210 215 220
Asp Ala Ala Arg Glu Trp Leu Leu Pro Asn Tyr Gln Arg Pro Asn Leu
225 230 235 240
Ser Val Leu Thr Gly Gln Tyr Val Gly Lys Val Leu Leu Ser Gln Asn
245 250 255
Ala Thr Thr Pro Arg Ala Val Gly Val Glu Phe Gly Thr His Lys Gly
260 265 270
Asn Phe His Asn Val Thr Ala Lys His Glu Val Leu Leu Ala Ala Gly
275 280 285
Ser Ala Val Ser Pro Thr Ile Leu Glu Tyr Ser Gly Ile Gly Met Lys
290 295 300
Ser Ile Leu Glu Pro Leu Gly Ile Lys Thr Val Val Asp Leu Pro Val
305 310 315 320
Gly Leu Asn Leu Gln Asp Gln Thr Thr Ser Thr Val Arg Ser Arg Ile
325 330 335
Thr Ser Ala Gly Ala Gly Gln Gly Gln Ala Ala Trp Phe Ala Thr Phe
340 345 350
Asn Glu Thr Phe Gly Asp Tyr Thr Glu Lys Ala His Glu Leu Leu Asn
355 360 365
Thr Lys Leu Glu Gln Trp Ala Glu Glu Ala Val Ala Arg Gly Gly Phe
370 375 380
His Asn Thr Thr Ala Leu Leu Ile Gln Tyr Glu Asn Tyr Arg Asp Trp
385 390 395 400
Ile Val Lys Asp Asn Val Ala Tyr Ser Glu Leu Phe Leu Asp Thr Ala
405 410 415
Gly Glu Ala Ser Phe Asp Val Trp Asp Leu Leu Pro Phe Thr Arg Gly
420 425 430
Tyr Val His Ile Leu Asp Lys Asp Pro Tyr Leu Arg His Phe Ala Tyr
435 440 445
Asp Pro Gln Tyr Phe Leu Asn Glu Leu Asp Leu Leu Gly Gln Ala Ala
450 455 460
Ala Thr Gln Leu Ala Arg Asn Ile Ser Asn Ser Gly Ala Met Gln Thr
465 470 475 480
Tyr Phe Ala Gly Glu Thr Ile Pro Gly Asp Asn Leu Ala Tyr Asp Ala
485 490 495
Asn Leu Arg Ala Trp Val Glu Tyr Ile Pro Tyr His Phe Arg Pro Asn
500 505 510
Tyr His Gly Val Gly Thr Cys Ser Met Met Pro Lys Glu Met Gly Gly
515 520 525
Val Val Asp Asn Ala Ala Arg Val Tyr Gly Val Gln Gly Leu Arg Val
530 535 540
Ile Asp Gly Ser Ile Pro Pro Thr Gln Met Ser Ser His Val Met Thr
545 550 555 560
Val Phe Tyr Ala Met Ala Leu Lys Ile Ala Asp Ala Val Leu Ala Asp
565 570 575
Tyr Ala Ser Met Gln
580
<210> 15
<211> 1746
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
ggtattgagg cttccttgtt gactgaccca aaggaggtcg ccggtagaac tgttgactac 60
atcattgctg gtggtggatt gactggtttg gttgtcgctg ccagattgac tgagaaccca 120
gacatcaccg ttttggtcat tgagtccggt tcttacgaat ctgatagagg tcctatcatt 180
gaagacttga acgcttacgg taaaatcttc ggatcttccg ttgaccacgc ttacgagact 240
gtctgccttg ccactaacaa tagaaccgct ttgattagag ctggtaacgg tttgggtggt 300
tctactttgg ttaacggagg tacttggacc agaccacaca aggctcaagt tgactcttgg 360
gagaccgtct tcggtaacga aggttggaat tgggattctg tcgcagctta ctccttgcag 420
gccgagagag cccgtgctcc aaacgctaag caaatcgccg caggtcacta cttcaacgcc 480
tcctgtcacg gtattaacgg aactgttcac gctggtccaa gagacaccgg tgacgattac 540
tctcctatcg tcaaggcctt gatgtccgct gttgaaaaca gaggtgtccc aactaagaag 600
gacttgggtt gcggagaccc acatggtgtt tctatgttcc ctaacacctt gcacgaggac 660
caagtcagat ccgatgctgc ccgtgaatgg ttgcttccaa actaccaaag acctaacttg 720
caggttttga ccggtcaata cgttggtaag gtccttttgt ctcaaaacgc cactacccca 780
agagctgttg gtgtcgagtt cggaactcac aagggtaact ttcacaatgt taccgctaaa 840
cacgaagtcc ttttggcagc tggttccgct gtttctccaa ctatcttgga gtactctggt 900
atcggaatga agtccatttt ggaaccactt ggtattaaga ccgtcgttga cttgcctgtt 960
ggtctgaact tgcaagacca gactacctct actgtcagat cccgtattac ctccgccggt 1020
gctggacagg gtcaggctgc ctggtttgct actttcaacg agaccttcgg tgactacact 1080
gagaaggctc acgaattgct taacaccaaa ttggaacaat gggctgagga agccgttgct 1140
agaggtggtt tccacaacac taccgctctt ttgatccaat acgagaacta cagagactgg 1200
attgttaagg ataacgtcgc ttactctgaa ttgttcttgg acactgccgg tgaggcttcc 1260
ttcgacgtct gggacttgct gccattcact agaggatacg ttcacatctt ggacaaggac 1320
ccatacttga gacacttcgc ttacgatcct caatacttct tgaacgagtt ggacttgctt 1380
ggtcaggctg ccgctactca attggctaga aacatctcta actccggtgc catgcaaact 1440
tactttgctg gtgaaaccat tccaggtgac aacttggcct acgatgctaa cttgagagct 1500
tgggttgaat acattccata ccacttcaga cctaactacc atggtgtcgg aacctgttct 1560
atgatgccaa aggagatggg tggtgtcgtt gacaacgccg ctagagttta cggtgtccag 1620
ggattgagag ttatcgacgg ttctatccca cctactcaaa tgtcctctca cgttatgacc 1680
gtcttctacg ctatggcttt gaagatcgca gacgctgttt tggctgacta cgcctccatg 1740
caataa 1746
<210> 16
<211> 581
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 16
Gly Ile Glu Ala Ser Leu Leu Thr Asp Pro Lys Glu Val Ala Gly Arg
1 5 10 15
Thr Val Asp Tyr Ile Ile Ala Gly Gly Gly Leu Thr Gly Leu Val Val
20 25 30
Ala Ala Arg Leu Thr Glu Asn Pro Asp Ile Thr Val Leu Val Ile Glu
35 40 45
Ser Gly Ser Tyr Glu Ser Asp Arg Gly Pro Ile Ile Glu Asp Leu Asn
50 55 60
Ala Tyr Gly Lys Ile Phe Gly Ser Ser Val Asp His Ala Tyr Glu Thr
65 70 75 80
Val Cys Leu Ala Thr Asn Asn Arg Thr Ala Leu Ile Arg Ala Gly Asn
85 90 95
Gly Leu Gly Gly Ser Thr Leu Val Asn Gly Gly Thr Trp Thr Arg Pro
100 105 110
His Lys Ala Gln Val Asp Ser Trp Glu Thr Val Phe Gly Asn Glu Gly
115 120 125
Trp Asn Trp Asp Ser Val Ala Ala Tyr Ser Leu Gln Ala Glu Arg Ala
130 135 140
Arg Ala Pro Asn Ala Lys Gln Ile Ala Ala Gly His Tyr Phe Asn Ala
145 150 155 160
Ser Cys His Gly Ile Asn Gly Thr Val His Ala Gly Pro Arg Asp Thr
165 170 175
Gly Asp Asp Tyr Ser Pro Ile Val Lys Ala Leu Met Ser Ala Val Glu
180 185 190
Asp Arg Gly Val Pro Thr Lys Lys Asp Leu Gly Cys Gly Asp Pro His
195 200 205
Gly Val Ser Met Phe Pro Asn Thr Leu His Glu Asp Gln Val Arg Ser
210 215 220
Asp Ala Ala Arg Glu Trp Leu Leu Pro Asn Tyr Gln Arg Pro Asn Leu
225 230 235 240
Ser Val Leu Thr Gly Gln Tyr Val Gly Lys Val Leu Leu Ser Gln Asn
245 250 255
Ala Thr Thr Pro Arg Ala Val Gly Val Glu Phe Gly Thr His Lys Gly
260 265 270
Asn Phe His Asn Val Thr Ala Lys His Glu Val Leu Leu Ala Ala Gly
275 280 285
Ser Ala Val Ser Pro Thr Ile Leu Glu Tyr Ser Gly Ile Gly Met Lys
290 295 300
Ser Ile Leu Glu Pro Leu Gly Ile Lys Thr Val Val Asp Leu Pro Val
305 310 315 320
Gly Leu Asn Leu Gln Asp Gln Thr Thr Ser Thr Val Arg Ser Arg Ile
325 330 335
Thr Ser Ala Gly Ala Gly Gln Gly Gln Ala Ala Trp Phe Ala Thr Phe
340 345 350
Asn Glu Thr Phe Gly Asp Tyr Thr Glu Gln Ala His Glu Leu Leu Asn
355 360 365
Thr Lys Leu Glu Gln Trp Ala Glu Glu Ala Val Ala Arg Gly Gly Phe
370 375 380
His Asn Thr Thr Ala Leu Leu Ile Gln Tyr Glu Asn Tyr Arg Asp Trp
385 390 395 400
Ile Val Lys Asp Asn Val Ala Tyr Ser Glu Leu Phe Leu Asp Thr Ala
405 410 415
Gly Glu Ala Ser Phe Asp Val Trp Asp Leu Leu Pro Phe Thr Arg Gly
420 425 430
Tyr Val His Ile Leu Asp Lys Asp Pro Tyr Leu Arg His Phe Ala Tyr
435 440 445
Asp Pro Gln Tyr Phe Leu Asn Glu Leu Asp Leu Leu Gly Gln Ala Ala
450 455 460
Ala Thr Gln Leu Ala Arg Asn Ile Ser Asn Ser Gly Ala Met Gln Thr
465 470 475 480
Tyr Phe Ala Gly Glu Thr Ile Pro Gly Asp Asn Leu Ala Tyr Asp Ala
485 490 495
Asn Leu Arg Ala Trp Val Glu Tyr Ile Pro Tyr His Phe Arg Pro Asn
500 505 510
Tyr His Gly Val Gly Thr Cys Ser Met Met Pro Lys Glu Met Gly Gly
515 520 525
Val Val Asp Asn Ala Ala Arg Val Tyr Gly Val Gln Gly Leu Arg Val
530 535 540
Ile Asp Gly Ser Ile Pro Pro Thr Gln Met Ser Ser His Val Met Thr
545 550 555 560
Val Phe Tyr Ala Met Ala Leu Lys Ile Ala Asp Ala Val Leu Ala Asp
565 570 575
Tyr Ala Ser Met Gln
580
<210> 17
<211> 1746
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 17
ggtattgagg cttccttgtt gactgaccca aaggaggtcg ccggtagaac tgttgactac 60
atcattgctg gtggtggatt gactggtttg gttgtcgctg ccagattgac tgagaaccca 120
gacatcaccg ttttggtcat tgagtccggt tcttacgaat ctgatagagg tcctatcatt 180
gaagacttga acgcttacgg taaaatcttc ggatcttccg ttgaccacgc ttacgagact 240
gtctgccttg ccactaacaa tagaaccgct ttgattagag ctggtaacgg tttgggtggt 300
tctactttgg ttaacggagg tacttggacc agaccacaca aggctcaagt tgactcttgg 360
gagaccgtct tcggtaacga aggttggaat tgggattctg tcgcagctta ctccttgcag 420
gccgagagag cccgtgctcc aaacgctaag caaatcgccg caggtcacta cttcaacgcc 480
tcctgtcacg gtattaacgg aactgttcac gctggtccaa gagacaccgg tgacgattac 540
tctcctatcg tcaaggcctt gatgtccgct gttgaagaca gaggtgtccc aactaagaag 600
gacttgggtt gcggagaccc acatggtgtt tctatgttcc ctaacacctt gcacgaggac 660
caagtcagat ccgatgctgc ccgtgaatgg ttgcttccaa actaccaaag acctaacttg 720
caggttttga ccggtcaata cgttggtaag gtccttttgt ctcaaaacgc cactacccca 780
agagctgttg gtgtcgagtt cggaactcac aagggtaact ttcacaatgt taccgctaaa 840
cacgaagtcc ttttggcagc tggttccgct gtttctccaa ctatcttgga gtactctggt 900
atcggaatga agtccatttt ggaaccactt ggtattaaga ccgtcgttga cttgcctgtt 960
ggtctgaact tgcaagacca gactacctct actgtcagat cccgtattac ctccgccggt 1020
gctggacagg gtcaggctgc ctggtttgct actttcaacg agaccttcgg tgactacact 1080
gagcaagctc acgaattgct taacaccaaa ttggaacaat gggctgagga agccgttgct 1140
agaggtggtt tccacaacac taccgctctt ttgatccaat acgagaacta cagagactgg 1200
attgttaagg ataacgtcgc ttactctgaa ttgttcttgg acactgccgg tgaggcttcc 1260
ttcgacgtct gggacttgct gccattcact agaggatacg ttcacatctt ggacaaggac 1320
ccatacttga gacacttcgc ttacgatcct caatacttct tgaacgagtt ggacttgctt 1380
ggtcaggctg ccgctactca attggctaga aacatctcta actccggtgc catgcaaact 1440
tactttgctg gtgaaaccat tccaggtgac aacttggcct acgatgctaa cttgagagct 1500
tgggttgaat acattccata ccacttcaga cctaactacc atggtgtcgg aacctgttct 1560
atgatgccaa aggagatggg tggtgtcgtt gacaacgccg ctagagttta cggtgtccag 1620
ggattgagag ttatcgacgg ttctatccca cctactcaaa tgtcctctca cgttatgacc 1680
gtcttctacg ctatggcttt gaagatcgca gacgctgttt tggctgacta cgcctccatg 1740
caataa 1746
<210> 18
<211> 581
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 18
Gly Ile Glu Ala Ser Leu Leu Thr Asp Pro Lys Glu Val Ala Gly Arg
1 5 10 15
Thr Val Asp Tyr Ile Ile Ala Gly Gly Gly Leu Thr Gly Leu Val Val
20 25 30
Ala Ala Arg Leu Thr Glu Asn Pro Asp Ile Thr Val Leu Val Ile Glu
35 40 45
Ser Gly Ser Tyr Glu Ser Asp Arg Gly Pro Ile Ile Glu Asp Leu Asn
50 55 60
Ala Tyr Gly Lys Ile Phe Gly Ser Ser Val Asp His Ala Tyr Glu Thr
65 70 75 80
Val Cys Leu Ala Thr Asn Asn Arg Thr Ala Leu Ile Arg Ala Gly Asn
85 90 95
Gly Leu Gly Gly Ser Thr Leu Val Asn Gly Gly Thr Trp Thr Arg Pro
100 105 110
His Lys Ala Gln Val Asp Ser Trp Glu Thr Val Phe Gly Asn Glu Gly
115 120 125
Trp Asn Trp Asp Ser Val Ala Ala Tyr Ser Leu Gln Ala Glu Arg Ala
130 135 140
Arg Ala Pro Asn Ala Lys Gln Ile Ala Ala Gly His Tyr Phe Asn Ala
145 150 155 160
Ser Cys His Gly Ile Asn Gly Thr Val His Ala Gly Pro Arg Asp Thr
165 170 175
Gly Asp Asp Tyr Ser Pro Ile Val Lys Ala Leu Met Ser Ala Val Glu
180 185 190
Asp Arg Gly Val Pro Thr Lys Lys Asp Leu Gly Cys Gly Asp Pro His
195 200 205
Gly Val Ser Met Phe Pro Asn Thr Leu His Glu Asp Gln Val Arg Ser
210 215 220
Asp Ala Ala Arg Glu Trp Leu Leu Pro Asn Tyr Gln Arg Pro Asn Leu
225 230 235 240
Ser Val Leu Thr Gly Gln Tyr Val Gly Lys Val Leu Leu Ser Gln Asn
245 250 255
Ala Thr Thr Pro Arg Ala Val Gly Val Glu Phe Gly Thr His Lys Gly
260 265 270
Asn Phe His Asn Val Thr Ala Lys His Glu Val Leu Leu Ala Ala Gly
275 280 285
Ser Ala Val Ser Pro Thr Ile Leu Glu Tyr Ser Gly Ile Gly Met Lys
290 295 300
Ser Ile Leu Glu Pro Leu Gly Ile Lys Thr Val Val Asp Leu Pro Val
305 310 315 320
Gly Leu Asn Leu Gln Asp Gln Thr Thr Ser Thr Val Arg Ser Arg Ile
325 330 335
Thr Ser Ala Gly Ala Gly Gln Gly Gln Ala Ala Trp Phe Ala Thr Phe
340 345 350
Asn Glu Thr Phe Gly Asp Tyr Thr Glu Lys Ala His Glu Leu Leu Asn
355 360 365
Thr Lys Leu Glu Gln Trp Ala Glu Glu Ala Val Ala Arg Gly Gly Phe
370 375 380
His Asn Thr Thr Ala Leu Leu Ile Gln Tyr Glu Asn Tyr Arg Asp Trp
385 390 395 400
Ile Val Lys Asp Asn Val Ala Tyr Ser Glu Leu Phe Leu Asp Thr Ala
405 410 415
Gly Glu Ala Ser Phe Asp Val Trp Asp Leu Leu Pro Phe Thr Arg Gly
420 425 430
Tyr Val His Ile Leu Asp Lys Asp Pro Tyr Leu Arg His Phe Ala Tyr
435 440 445
Asp Pro Gln Tyr Phe Leu Asn Glu Leu Asp Leu Leu Gly Gln Ala Ala
450 455 460
Ala Thr Gln Leu Ala Arg Asn Ile Ser Asn Ser Gly Ala Met Gln Thr
465 470 475 480
Tyr Phe Ala Gly Glu Thr Ile Pro Gly Asp Asn Leu Ala Tyr Asp Ala
485 490 495
Asn Leu Arg Ala Trp Val Glu Tyr Ile Pro Tyr His Phe Arg Pro Asn
500 505 510
Tyr His Gly Val Gly Thr Cys Ser Met Met Pro Lys Glu Met Gly Gly
515 520 525
Val Val Asp Asn Ala Ala Asn Val Tyr Gly Val Gln Gly Leu Arg Val
530 535 540
Ile Asp Gly Ser Ile Pro Pro Thr Gln Met Ser Ser His Val Met Thr
545 550 555 560
Val Phe Tyr Ala Met Ala Leu Lys Ile Ala Asp Ala Val Leu Ala Asp
565 570 575
Tyr Ala Ser Met Gln
580
<210> 19
<211> 1746
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 19
ggtattgagg cttccttgtt gactgaccca aaggaggtcg ccggtagaac tgttgactac 60
atcattgctg gtggtggatt gactggtttg gttgtcgctg ccagattgac tgagaaccca 120
gacatcaccg ttttggtcat tgagtccggt tcttacgaat ctgatagagg tcctatcatt 180
gaagacttga acgcttacgg taaaatcttc ggatcttccg ttgaccacgc ttacgagact 240
gtctgccttg ccactaacaa tagaaccgct ttgattagag ctggtaacgg tttgggtggt 300
tctactttgg ttaacggagg tacttggacc agaccacaca aggctcaagt tgactcttgg 360
gagaccgtct tcggtaacga aggttggaat tgggattctg tcgcagctta ctccttgcag 420
gccgagagag cccgtgctcc aaacgctaag caaatcgccg caggtcacta cttcaacgcc 480
tcctgtcacg gtattaacgg aactgttcac gctggtccaa gagacaccgg tgacgattac 540
tctcctatcg tcaaggcctt gatgtccgct gttgaagaca gaggtgtccc aactaagaag 600
gacttgggtt gcggagaccc acatggtgtt tctatgttcc ctaacacctt gcacgaggac 660
caagtcagat ccgatgctgc ccgtgaatgg ttgcttccaa actaccaaag acctaacttg 720
caggttttga ccggtcaata cgttggtaag gtccttttgt ctcaaaacgc cactacccca 780
agagctgttg gtgtcgagtt cggaactcac aagggtaact ttcacaatgt taccgctaaa 840
cacgaagtcc ttttggcagc tggttccgct gtttctccaa ctatcttgga gtactctggt 900
atcggaatga agtccatttt ggaaccactt ggtattaaga ccgtcgttga cttgcctgtt 960
ggtctgaact tgcaagacca gactacctct actgtcagat cccgtattac ctccgccggt 1020
gctggacagg gtcaggctgc ctggtttgct actttcaacg agaccttcgg tgactacact 1080
gagaaggctc acgaattgct taacaccaaa ttggaacaat gggctgagga agccgttgct 1140
agaggtggtt tccacaacac taccgctctt ttgatccaat acgagaacta cagagactgg 1200
attgttaagg ataacgtcgc ttactctgaa ttgttcttgg acactgccgg tgaggcttcc 1260
ttcgacgtct gggacttgct gccattcact agaggatacg ttcacatctt ggacaaggac 1320
ccatacttga gacacttcgc ttacgatcct caatacttct tgaacgagtt ggacttgctt 1380
ggtcaggctg ccgctactca attggctaga aacatctcta actccggtgc catgcaaact 1440
tactttgctg gtgaaaccat tccaggtgac aacttggcct acgatgctga cttgagagct 1500
tgggttgaat acattccata ccacttcaga cctaactacc atggtgtcgg aacctgttct 1560
atgatgccaa aggagatggg tggtgtcgtt gacaacgccg ctaacgttta cggtgtccag 1620
ggattgagag ttatcgacgg ttctatccca cctactcaaa tgtcctctca cgttatgacc 1680
gtcttctacg ctatggcttt gaagatcgca gacgctgttt tggctgacta cgcctccatg 1740
caataa 1746
<210> 20
<211> 30
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 20
ggtattgagg cttccttgtt gactgaccca 30
<210> 21
<211> 30
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 21
ttgcatggag gcgtagtcag ccaaaacagc 30
<210> 22
<211> 32
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 22
tggaccagac catctaaggc tcaagttgac tc 32
<210> 23
<211> 32
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 23
aacttgagcc ttagatggtc tggtccaagt ac 32
<210> 24
<211> 32
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 24
tccgctgttg aaaacgatgg tgtcccaact aa 32
<210> 25
<211> 32
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 25
tgggacacca tcgttttcaa cagcggacat ca 32
<210> 26
<211> 32
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 26
gactacactg agcaagctca cgaattgctt aa 32
<210> 27
<211> 32
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 27
caattcgtga gcttgctcag tgtagtcacc ga 32
<210> 28
<211> 32
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 28
caattcgtga gcttgctcag tgtagtcacc ga 32
<210> 29
<211> 32
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 29
ccaagcatcc aagttagcat cgtaggccaa gt 32
<210> 30
<211> 32
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 30
gacaacgccg ctaacgttta cggtgtccag gg 32
<210> 31
<211> 31
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 31
gacaccgtaa acgttagcgg cgttgtcaac g 31
Claims (10)
1. The glucose oxidase GoxM10 mutant with improved acid stability is characterized in that the mutant has an amino acid sequence obtained by carrying out H113S or D193N or K362Q or D497N or R535N mutation on glucose oxidase GoxM10 with an amino acid sequence shown as SEQ ID NO: 1.
2. The glucose oxidase GoxM10 mutant with improved acid stability according to claim 1, wherein the mutant has an amino acid sequence obtained by subjecting glucose oxidase GoxM10 with an amino acid sequence shown as SEQ ID NO. 1 to H113S/D497N, D193N/D497N, K362Q/D497N or D497N/R535N mutation.
3. A glucose oxidase gene encoding the enzyme GoxM10 mutant with improved acid stability according to claim 1 or 2.
4. The glucose oxidase gene of claim 3, wherein the nucleotide sequence of the gene is as shown in SEQ ID NO 3 or 5 or 7 or 9 or 11 or 13 or 15 or 17 or 19.
5. A recombinant vector comprising the glucose oxidase gene of claim 3.
6. A recombinant strain comprising the glucose oxidase gene of claim 3.
7. A method of making a glucose oxidase having improved acid stability, comprising the steps of:
constructing a recombinant vector comprising a gene encoding the glucose oxidase GoxM10 mutant with improved acid stability according to claim 1 or 2;
introducing the recombinant vector into a host cell;
inducing expression and separating glucose oxidase.
8. A method for improving the acid stability of glucose oxidase is characterized in that the method comprises the step of carrying out H113S or D193N or K362Q or D497N or R535N mutation on glucose oxidase GoxM10 with the amino acid sequence shown as SEQ ID NO: 1.
9. The method of improving the acid stability of glucose oxidase according to claim 8, comprising:
carrying out H113S/D497N mutation on glucose oxidase GoxM10 with the amino acid sequence shown as SEQ ID NO: 1; or
Carrying out D193N/D497N mutation on glucose oxidase GoxM10 with the amino acid sequence shown as SEQ ID NO: 1; or
A step of mutating a glucose oxidase GoxM10 having an amino acid sequence shown in SEQ ID NO:1 into K362Q/D497N; or
Carrying out D497N/R535N mutation on glucose oxidase GoxM10 with the amino acid sequence shown as SEQ ID NO: 1.
10. Use of the glucose oxidase GoxM10 mutant with improved acid stability as claimed in claim 1 or 2 as feed additive and food additive.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210648724.1A CN114736880B (en) | 2022-06-09 | 2022-06-09 | Mutant D497N of glucose oxidase GoxM10 with improved acid stability as well as derivative mutant and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210648724.1A CN114736880B (en) | 2022-06-09 | 2022-06-09 | Mutant D497N of glucose oxidase GoxM10 with improved acid stability as well as derivative mutant and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114736880A true CN114736880A (en) | 2022-07-12 |
CN114736880B CN114736880B (en) | 2022-09-27 |
Family
ID=82287778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210648724.1A Active CN114736880B (en) | 2022-06-09 | 2022-06-09 | Mutant D497N of glucose oxidase GoxM10 with improved acid stability as well as derivative mutant and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114736880B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101528766A (en) * | 2006-08-04 | 2009-09-09 | 维莱尼姆公司 | Glucanases, nucleic acids encoding them and methods for making and using them |
CN101629204A (en) * | 2003-03-31 | 2010-01-20 | 诺维信股份有限公司 | Methods for producing biological substances in enzyme-deficient mutants of aspergillus |
AR101611A1 (en) * | 2014-08-21 | 2016-12-28 | Dsm Ip Assets Bv | GLUCOSE OXIDASES TO IMPROVE THE BAKING |
US20180186882A1 (en) * | 2014-10-14 | 2018-07-05 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
US20180222982A1 (en) * | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
CN110577939A (en) * | 2018-06-07 | 2019-12-17 | 青岛红樱桃生物技术有限公司 | glucose oxidase mutant with improved heat resistance as well as coding gene and application thereof |
CN110651048A (en) * | 2017-04-11 | 2020-01-03 | 诺维信公司 | Glucoamylase variants and polynucleotides encoding same |
CN112301009A (en) * | 2019-07-26 | 2021-02-02 | 中国农业科学院北京畜牧兽医研究所 | Glucose oxidase mutant GOD with improved heat stability as well as gene and application thereof |
CN113862233A (en) * | 2021-12-03 | 2021-12-31 | 中国农业科学院北京畜牧兽医研究所 | Method for improving acid stability of glucose oxidase, mutant Q241E/R499E, gene and application |
-
2022
- 2022-06-09 CN CN202210648724.1A patent/CN114736880B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101629204A (en) * | 2003-03-31 | 2010-01-20 | 诺维信股份有限公司 | Methods for producing biological substances in enzyme-deficient mutants of aspergillus |
CN101528766A (en) * | 2006-08-04 | 2009-09-09 | 维莱尼姆公司 | Glucanases, nucleic acids encoding them and methods for making and using them |
AR101611A1 (en) * | 2014-08-21 | 2016-12-28 | Dsm Ip Assets Bv | GLUCOSE OXIDASES TO IMPROVE THE BAKING |
US20180186882A1 (en) * | 2014-10-14 | 2018-07-05 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
US20180222982A1 (en) * | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
CN110651048A (en) * | 2017-04-11 | 2020-01-03 | 诺维信公司 | Glucoamylase variants and polynucleotides encoding same |
CN110577939A (en) * | 2018-06-07 | 2019-12-17 | 青岛红樱桃生物技术有限公司 | glucose oxidase mutant with improved heat resistance as well as coding gene and application thereof |
CN112301009A (en) * | 2019-07-26 | 2021-02-02 | 中国农业科学院北京畜牧兽医研究所 | Glucose oxidase mutant GOD with improved heat stability as well as gene and application thereof |
CN113862233A (en) * | 2021-12-03 | 2021-12-31 | 中国农业科学院北京畜牧兽医研究所 | Method for improving acid stability of glucose oxidase, mutant Q241E/R499E, gene and application |
Non-Patent Citations (2)
Title |
---|
曾庆梅等: "黑曲霉酸性α-淀粉酶基因的克隆及其在毕赤酵母中的表达", 《食品科学》 * |
闻一凡等: "定点突变提高毕赤酵母产葡萄糖氧化酶的氧化稳定性", 《食品与生物技术学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023225459A2 (en) | 2022-05-14 | 2023-11-23 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
Also Published As
Publication number | Publication date |
---|---|
CN114736880B (en) | 2022-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114736879B (en) | Glucose oxidase GoxM10 mutant E361P with improved heat stability and derivative mutant and application thereof | |
EP4006149A1 (en) | Mutant glucose oxidase (god) having improved thermal stability and gene and application thereof | |
CN113862233B (en) | Method for improving acid stability of glucose oxidase, mutant Q241E/R499E, gene and application | |
CN112725307A (en) | Low-temperature inulase exonuclease mutant MutG169 delta 4 with reduced heat resistance and application thereof | |
CN114736880B (en) | Mutant D497N of glucose oxidase GoxM10 with improved acid stability as well as derivative mutant and application thereof | |
CN114736881B (en) | Glucose oxidase GoxM10 mutant A4D with improved acid stability and derivative mutant and application thereof | |
CN117625581A (en) | N-acetylglucosaminidase mutant Ea2F and application thereof | |
CN113430181B (en) | Bacterial laccase derived from Asian elephant intestinal metagenome and gene thereof | |
CN113493799B (en) | Aspergillus niger strain for high yield of acid lactase | |
CN110283797B (en) | Tyrosinase, gene, engineering bacterium and preparation method thereof | |
CN108795891B (en) | Glucose oxidase CnGODA as well as gene and application thereof | |
CN113564151B (en) | Method for improving structural isomerism catalytic activity of CE enzyme and mutant thereof | |
CN112877306A (en) | Super heat-resistant glucose oxidase AtGOD, gene and application thereof | |
CN114107270B (en) | L-aspartic acid beta-decarboxylase mutant | |
CN114686409B (en) | Method for enhancing expression of superoxide dismutase gene and improving glutamine transaminase yield | |
CN116731989B (en) | Laccase mutant, genetically engineered bacterium and application thereof | |
CN114574511B (en) | Extremely heat-resistant xylanase gene, extremely heat-resistant xylanase and application thereof | |
AU2021100409A4 (en) | Recombinant low-temperature catalase, recombinant vector and engineered strain thereof | |
CN114621944B (en) | Arginine deiminase mutant with improved enzyme activity | |
CN102409033B (en) | N-carbamyl-L-cysteine (L-NCC) amidohydrolase, encoding gene and application of recombinant expressed protein of L-NCC amidohydrolase | |
CN111394331B (en) | Glutamine transaminase, coding gene, expression vector and recombinant bacterium thereof | |
CN110066814B (en) | beta-D-glucosidase gene and encoding protein thereof | |
CN114686410A (en) | Glutamine transaminase high-producing strain for enhancing 1-phosphofructokinase gene transcription level and preparation and fermentation methods thereof | |
CN115927267A (en) | Bile acid complex enzyme preparation and application thereof in preparation of feed additive for improving digestibility of animal protein | |
CN118360224A (en) | Construction method and application of acetoin-producing engineering strain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |